Rita Alloway

Rita R Alloway

Research Professor of Nephrology

Medical Sciences Building

6203

COM IM Nephrology - 0585

Medical Sciences Building
Room 6203
Cincinnati, Ohio 45267-0585

Professional Summary

RITA ALLOWAY, PharmD, BCPS OFFICE ADDRESS College of Medicine Department of Internal Medicine Div. of Nephrology & Hypertension 231 Albert Sabin Way Medical Sciences Building Suite G163, ML 585 P.O. Box 670585 Cincinnati Ohio 45267-0585 Office: 513.558.1568 Fax: 513.558.4944 Email: rita.alloway@uc.edu

Education

Oral Roberts University 1984 (Pre-Pharmacy Curriculum)

Doctoral Degree, University of Tennessee College of Pharmacy 1988

Residency, Veteran's Administration Medical Center 1989

Positions and Work Experience

2000 -To Present Research Professor, Department of Internal Medicine, Division of Nephrology and Hypertension, Section of Transplantation, University of Cincinnati, Cincinnati, OH

1997 -2000 Associate Professor, Department of Clinical Pharmacy , University of Tennessee College of Pharmacy, Memphis, TN

1997 -2000 Associate Professor, Department of Surgery, University of Tennessee College of Medicine, Memphis, TN

1989 -1997 Assistant Professor, Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis, TN

Research and Practice Interests

Kidney, Liver and Pancreas Solid Organ Transplantation Pharmacotherapy with the Goal of Individualizing Transplant Recipients' Immunosuppressive Regimens Based Upon Pharmacogenomic and Pharmacokinetic Immunosuprression Characterization, Novel Clinical Trial Design, Study Conduct Strategies with a Focus on Pharmacokinetic Studies

Research Support

Investigators:Alloway 2011 -2013 NIH subcontract from University of Pittsburgh Immune Monitoring after Thymoglobulin of Basiliximab Induction in Living Donor Kidney Transplantation. Role:Co-Investigator

Investigators:Alloway 2012 -2013 FDA, the American Epilepsy Society and the Epilepsy Foundation via sponsored programs at University of Cincinnati EQUIGEN generic antiepilieptic drug equivalence trials Role:Consultant

Investigators:Alloway 2011 -2013 Alexion Pharmaceuticals, Inc A randomized, open-label, multicenter trial to determine safety and efficacy of eculizumab in the prevention of acute humoral rejection (AHR) in living donor kidney transplant recipients requiring desensitization therapy. Role:Co-Investigator

Investigators:Alloway 2010 -2013 Novartis Pharmaceuticals A partially blinded, prospective, randomized multicenter study evaluating efficacy, safety and tolerability of oral sotrastaurin plus standard or reduced exposure tacrolimus vs myfortic® plus tacrolimus in de novo renal transplant recipients Role:Co-Investigator

Investigators:Alloway 2010 -2013 Novartis Pharmaceuticals A 24-month randomized, multicenter study evaluating efficacy, safety, tolerability and pharmacokinetics of sotrastaurin (STN) combined with tacrolimus vs. a tacrolimus/mycophenolate mofetil )MMF)-based control regimen in de novo liver transplant recipients Role:Co-Investigator

Investigators:Alloway 2010 -2013 Ethicon Pilot Study to Evaluate the Effects of Irreversible Electroporation (IRE) on Explanted Human Liver Tissue Role:Co-Investigator

Investigators:Alloway 2010 -2013 Nycomed A randomized, open label, parallel-group, multi-center trial to compare the efficacy and safety of TachoSilÒ versus standard hemostatic fleece material for the secondary treatment of local bleeding in hepatic resection surgery Role:Co-Investigator

Investigators:Alloway 2010 -2013 NIH collaboration, Cardiology Collection and Storage of Omental, Subcutaneous, Per-renal, Mesenteric and/or other Adipose Specimens from Patients at the University of Cincinnati Role:Co-Investigator

Investigators:Alloway 2008 -2011 Astellas Influence of Immunosuppression on the Biologic Behavior of De-Novo Recurrent Cancers in Organ Transplant Recipients Role:Co-Investigator

Investigators:Alloway 2010 -2013 Novartis Pharmaceuticals A 12-month, prospective, randomized, dual center, open label pilot study to evaluate the safety and efficacy of Myfortic® (mycophenolic acid) loading regimens in combination with Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)] or Simulect® (basiliximab) induction and Prograf® (tacrolimus) in early corticosteroid withdrawal. Role:Co-Investigator

Investigators:Alloway 2009 -2012 Wyeth Pharmaceuticals, Now Pfizer Planned Transition to Sirolimus-Based Therapy Versus Continued Tacrolimus-Based Therapy in Renal Allograft Recipients Role:Sub-Investigator

Investigators:Alloway 2008 -2012 Genzyme/Millenium Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B Cell Depleting Therapy in Combination with Anti-Thymocyte Globulin [Rabbit} (Thymoglobulin®, Genzyme), Tacrolimus (prograd®, Astellas), Mycophenolate Mofetil (Cellcept®, Roche) and Corticosteroid Minimization. Role:Co-Investigator

Investigators:Alloway 2008 -2012 Genzyme/Millenium B-Cell Targeted Therapy for Acute Renal Allograft Rejection with an Antibody Mediated Component: A Prospective, Randomized, Open-Label Study Role:Co-Investigator

Investigators:Alloway 2007 -2009 Kidney Foundation of Ohio (Greater Cincinnati) An Appropriate Assessment of Kidney Function in Patients with End Stage Liver Disease-The Role of Cystatin C. Role:Co-Investigator

Investigators:Alloway 2008 -2010 Millenium B-Cell Targeted Desensitization Strategy for Performed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation. Role:Co-Investigator

Investigators:Alloway 2012 -2015 Millenium Plasma Cell and Memory B Cell Therapy for Acute Antibody Mediated Rejection: A Prospective, Multicenter, Open Label Study Role:Co-Investigator Pending

Investigators:Alloway 2012 -2016 Bristol-Myers Squibb Company A Randomized, Open-Label, Multicenter Study of Belatacept-Based Early Corticosteroid Withdrawal Regimens in Renal Transplantation LEA CSWD Investigator Initiated Role:Cincinnati, OH Pending

Investigators:Alloway 2012 -2013 Vascular Access Clinical Trial Group (NIH and UCPC) Vascular Access Clinical Trial Group Investigator and Coordinator Operations Role:Consultant

Investigators:Alloway Cutter Biological Immunoglobulin Prophylaxis in Recipients of Solid Organ Transplants Role:Collaborating Investigator Completed

Investigators:Alloway Ortho Pharmaceuticals Randomized, Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy Role:PI Completed

Investigators:Alloway Burroughs Wellcome Company Oral 256U87 Suppression of Cytomegalovirus Infection and Disease in Renal Allograft Recipients Role:Collaborating Investigator Completed

Investigators:Alloway Sandoz Pharmaceuticals Corporation A Multicenter Randomized Comparative Study Comparing Sandimmune Oral Solution in the Prevention of Renal Allograft Recjection Role:Co-Principle Investigator Completed

Investigators:Alloway Boehringer Mannheim Pharmaceuticals A Placebo-Controlled, Double-Blind Random-Off Evaluation of the Efficacy of Oral Torsemide (Demadex) in Patients with Chronic Renal Insufficiency Role:Co-Investigator Completed

Investigators:Alloway Upjohn Company An Open-Label Safety and Tolerance Study of Peripheral Vein Administration of Equine Antithymocyte Globulin (ATGAM) Role:Co-Principle Investigator Completed

Investigators:Alloway Abbott Laboratories, Budget in Negotation IMx Tacrolimus Assay Investigation Device Evaluation Role:Collaborating Investigator Completed

Investigators:Alloway Sandoz Pharmaceuticals Corporation A Prospective, Randomized, Comparative Multicenter Safety and Tolerability Study of Neoral Versus Sandimmune in Primary Liver Transplant Patients Role:Co-Principle Investigator Completed

Investigators:Alloway Sangstat Medical Corporation A Double-blinded Randomized Multicenter Phase III Clinical Trial of Thymoglobulin Versus Atgam in the Treatment of Acute Graft Rejection Episodes following Renal Transplantation in Adults Role:Co-Principle Investigator Completed

Investigators:Alloway Fujisawa Pharmaceuticals Effects of FK-506 (Prograf) on Hyperlipidemia after Successful Renal Transplantation Role:Co-Principle Investigator Completed

Investigators:Alloway Sandoz Pharmaceuticals Corporation Multicenter, Open-Label Study of the Safety and Tolerability of Neoral in Stable Renal Transplant Patients Role:Co-Principle Investigator Completed

Investigators:Alloway Sandoz Pharmaceuticals Corporation A Multicenter, Randomized, Double-blinde, Placebo, Controlled Trial of SDZ CHI 621 for the Prevention of Acute Cellular Rejection in Renal Allograft Recipients Role:Co-Principle Investigator Completed

Investigators:Alloway Fujisawa Pharmaceuticals Pharmacokinetic and Primary Prophylaxis with Tacrolimus as Part of a Quadruple, Sequential Immunosuppressive Drug Regimen in Black Cadaveric Renal Transplant Recipients Role:Co-Principle Investigator Completed

Investigators:Alloway British Biotech A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of Two Doses of Lexipafant for the Treatment of Acute Pancreatitis Role:Collaborating Investigator Completed

Investigators:Alloway Fujisawa Pharmaceuticals An Open Labeled, Prosepective Study of the Effects of Tacrolimus Based Immunosuppressive Regimen as Primary Therapy in Liver Transplant Recipients Role:Co-Principle Investigator Completed

Investigators:Alloway Sangstat Medical Corporation An Open Label Single Center Comparison of Neoral and Generic Cyclosporine Bioequivalence in Stable Adult Renal Transplant Recipients Role:Co-Principle Investigator Completed

Investigators:Alloway Sangstat Medical Corporation An Open Label Single Center Comparison of Sandimmune and Generic Cyclosporine Bioequivalence in Stable Adult Renal Transplant Recipients Role:Co-Principle Investigator Completed

Investigators:Alloway Wyeth-Ayerst A Double-Blind, Comparative Study of the Effect of Two Dose Levels of Immunosuppressive Therapy, in Renal Allograft Recipients Role:Co-Principle Investigator Completed

Investigators:Alloway Ortho Biotech Five Year Follow-Up of a Prospective Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy in Renal Allograft Recipients Role:Co-Principle Investigator

Investigators:Alloway Medimmune Phase 1/2 Trial of Murine Monoclonal Antibody Medi-500 (T10B9) in the Treatment of Acute Renal Allograft Rejection Role:Co-Principle Investigator Completed

Investigators:Alloway Sangstat Medical Corporation A Pilot Comparative, Controlled Evaluation of the Monitoring of Cyclosporine in Whole Blood Peripheral Venous Samples Versus Filter Paper Extraction of Capillary Venous Samples Role:PI Completed

Investigators:Alloway Sangstat Medical Corporation An Open Label Single Center Comparison Long Term Generic Cyclosporine Administration in Stable Adult Renal Transplant Recipients Role:Co-Principle Investigator Completed

Investigators:Alloway Sangstat Medical Corporation Prospective Evaluation of Consecutive Renal Allograft Recipients Receiving a Quadruple, Sequential, Immunosuppressive Drug Regimen of Thymoglobulin, Sang-35 Oral Solution (Cyclosporine), Mycophenolate Mofetil, and Prednisone Role:Co-Principle Investigator Completed

Investigators:Alloway IMTIX A Phase III, Randomixed, Double-Blind, Placebo-Controlled Multicenter Study of the Efficacy of Odulimomab (ANTILFA) in Preventing Delayed Graft Function of Cadaveric Renal Allograft Patients Not Receiving Biological Induction Immunosuppressive Therapy Role:Co-Principle Investigator Completed

Investigators:Alloway Fujisawa Pharmaceuticals A Randomized Comparative Trial of the Effect of Antilymphocyte Induction on Tacrolimus Plus Mycophenolate Mofetil Maintenance Immunosuppression after Simultaneous Kidney Pancreas Transplantation Role:Co-Principle Investigator Completed

Investigators:Alloway NATCO Influence of Side Effect Profile on Compliance and Transplant Outcomes Role:Co-Investigator Completed

Investigators:Alloway Sangstat Medical Corporation A Prospective, Randomized, Multicenter, Controlled Study of the CycloTech Delivery Device in Stable Solid Organ Transplant Recipients Receiving SangCya (Cyclosporine Oral Solution, USP (modified) 100mg/mL) Role:PI Completed

Investigators:Alloway 1998 -2002 NIH, NR 004687 Post-Transplant Quality of Life Intervention Study Role:Co-Investigator

Investigators:Alloway Sangstat Medical Corporation An Open Label Pharmacokinetic Comparison of Sang-2000, SangCyA and Neoral in Stable Adult Renal Transplant Recipients Role:PI Completed

Investigators:Alloway Women's Health Management of Posttransplant Osteoporosis in Women Role:Co-Investigator Completed

Investigators:Alloway Roche Laboratories A Randomized, Open-Label, Multicenter, Efficacy and Safety Study of Pagasys for the Treatment of Hepatitis C Virus Infection Administered Six to Sixty Months Post-Liver Transplantation Role:Co-Investigator Completed

Investigators:Alloway Isotechnika A Phase 2, Randomized Multicenter, Double-Blind Safety Study of ISA 247 and Cyclosporine in Post Renal Transplant Patients Role:Co-Investigator Completed

Investigators:Alloway 2002 -2004 Wyeth-Ayerst Pharmaceutical Company An open-label study to evaluate the safety and efficacy of early (5 day) steroid cessation in de novo renal allograft recipients treated with Simulect induction and Prograf in combination with Rapamune Role:Co-Investigator Completed

Investigators:Alloway 2002 -2005 Roche Laboratories An open-label, comparative trial of two daclizumab dosing strategies versus no induction treatment in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute allograft rejection in simultaneous kidney/pancreas transplant recipients Role:Co-Principle Investigator Completed

Investigators:Alloway 08-2003 -08-2004 American College of Clinical Pharmacy Pharmacokinetics of Immunosuppressants in Transplant Patients Who Have Undergone Gastric Bypass Surgery Role:Preceptor, PI

Investigators:Alloway 2003 -2004 Paul Teschan Research Fund Prospective Monitoring for Polyomavirus Infection and Nephropathy in Kidney Transplant Recipients Role:Co-Investigator Completed

Investigators:Alloway 2003 -2004 NIH Grant Evaluation of Immune Globulin Intravenous, (Human), 10% Manufactured by Chromatography Process (IGIV-C, 10%), as an Agent to Reduce Anti-HLA Antibodies and Improve Transplantation Results in Cross Match Positive Living Donor Kidney Allograft Recipients Role:Co-Investigator Completed

Investigators:Alloway 2004 -2005 NCI Association of Polyoma Viruses (BKV, JCV, SV40) in Tumors of Immunosuppressed Patients with Post-Transplant Lymphoproliferative Disorder Role:Co-Investigator Completed

Investigators:Alloway 2003 -2006 IDUN Pharmaceuticals Safety, Tolerability and Efficacy of a Caspase Inhibitor, IDN-6556, in Patients Undergoing Orthotopic Liver Transplantation Role:Co-Investigator Completed

Investigators:Alloway 2004 -2008 Fujisawa Healthcare Incorporated A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients Role:Co-Investigator Completed

Investigators:Alloway 2005 -2007 Astellas A Phase II, Proof of Concept, Randomized, Open-Label, Two-Arm, Parallel-Group, Multicenter Study to Assess the Efficacy and Safety of FK 778 Compared with Standard Care in Renal Transplant Recipients with Untreated Biopsy Diagnosed BK Nephropathy Role:Co-Investigator Completed

Investigators:Alloway 2004 -2006 Sangstat Medical Corporation Randomized, Prospective, Phase II Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Therapy in Living Donor Renal Transplantation Using Mycophenolate Mofetil and Tacrolimus Maintenance Therapy Role:Co-Investigator Completed

Investigators:Alloway 2003 -2005 Wyeth-Ayerst Pharmaceutical Company Extension: A Prospective Pilot Study of Corticosteroid Avoidance with Prograf, CellCept and Rapamune that Avoids Induction Therapy in Renal Transplant Patients Role:PI Completed

Investigators:Alloway 2003 -2004 Fujisawa A Phase II, Open Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Heart Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen Role:PI Completed

Investigators:Alloway 2001 -2005 Roche Laboratories A Prospective, Pilot Study of Early Corticosteroid Cessation with Zenapax, Prograf, Cellcept and Rapamune in High Immunologic Risk Renal Transplant Recipients Role:Co-Investigator Completed

Investigators:Alloway 2001 -2004 Novartis Pharmaceutical Company A Multicenter, Randomized, Partially-Blinded Study of the Safety and Efficacy of FTY720 Combined with Corticosteroids and Full or Reduced Dose Neoral in De Novo Adult Renal Transplant Recipients Role:PI Completed

Investigators:Alloway 2002 -2006 Roche Laboratories Open-Label, Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection Role:Co-Investigator

Investigators:Alloway 2001 -2005 Wyeth-Ayerst Pharmaceutical Company Rapamune Outcomes Assessment Registry Role:PI Completed

Investigators:Alloway 2002 -2006 Fujisawa Pharmaceuticals A Single Center, Pilot Study of Corticosteroid Discontinuation in Liver Transplant Recipients Utilizing a Tacrolimus/Mycophenolate Mofetil Based Maintenance Immunosuppression Protocol Role:Co-Investigator Completed

Investigators:Alloway 2005 -2007 Novartis Pharmaceutical Company A One-Year, Multicenter, Open-Label, Randomized Study to Evaluate the Safety and the Efficacy of FTY720 Combined with Tacrolimus and Steroids, in Denovo Adult Renal Transplant Recipients Role:Co-Investigator Completed

Investigators:Alloway 2004 -2008 Roche Laboratories A Prospective, Randomized, Multicenter, Open-Label, Comparative Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon alfa-2a (Pagasys®) Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C Role:Co-Investigator Completed

Investigators:Alloway 2004 -To Present Roche Laboratories Recurrent Hepatitis C Re-Transplant Study Group Role:Co-Investigator Completed

Investigators:Alloway 2005 -2007 Genzyme A Randomized, Controlled, Multicenter Study of Thymoglobulin Induction Therapy with a Calcineurin Inhibitor Sparing Regimen in Liver Transplant Patients Role:Co-Investigator Completed

Investigators:Alloway 2006 -2008 Novartis, Investigator Initiated A 12-Month, Prospective, Non-Randomized, Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of Myfortic® in Combination with Tacrolimus and Thymoglobulin® in Early Corticosteroid Withdrawal Role:PI Completed

Investigators:Alloway 2005 -2007 Novartis A Six-Month, Prospective, Multicenter, Open-Label, Parallel, Randomized Study of the Safety, Tolerability and Efficacy of Myfortic with Simulect, Corticosteroids, and Two Different Levels of Tacrolimus in De Novo Renal Transplant Recipients Role:PI Completed

Investigators:Alloway 2005 -2007 Ys Therapeutics A Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Intravenous, Single-Dose, Dose-Escalation Study of the Safety, Pharmacokinetics, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation Role:Co-Investigator Completed

Investigators:Alloway 2003 -2009 Fujisawa Healthcare Incorporated A Phase III, randomized, open-label, comparative, multicenter study to assess the safety and efficacy of Prograf/MMF, Modified Release Prograf/MMF and Neoral/MMF in denovo kidney transplant recipients Role:PI Completed

Investigators:Alloway 2002 -2008 Fujisawa A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Kidney Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen Role:PI Completed

Investigators:Alloway 2002 -2008 Fujisawa A Phase II, Open-Label, Multicenter Study to Assess the Pharmacokinetics, Safety and Tolerability in Stable Liver Transplant Patients Converted from a Prograf Based Immunosuppression Regimen to a Modified Release (MR) Tacrolimus Based Immunosuppression Regimen Role:PI Completed

Investigators:Alloway 2002 -2008 Fujisawa Pharmaceuticals A prospective, randomized, multicenter trial of early corticosteroid cessation vs. long term maintenance corticosteroid therapy in primary renal allograft recipients treatment with tacrolimus and mycophenolate mofetil Role:Co-Investigator Completed

Investigators:Alloway 2002 -2007 Roche Laboratories Corticosteroid-free, Calcineurin-sparing Immunosuppression Protocol for HLA-Identical Living Donor Renal Transplant Recipients Role:PI Completed

Investigators:Alloway 2007 -2008 Novartis A 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus in combination with myfortic®, Simulect® and corticosteroids in de novo adult renal transplant recipients Role:Co-Investigator Completed

Investigators:Alloway 2007 -2008 LifeCycle Pharma A/S Phase 2, Open-label Multicenter Prospective, Conversion Study in Stable Kidney Transplant Patients to Compare the Pharmacokinetic of LC_-Tacro tablets Once a day to Prograf Capsules Twice a day Role:Co-Investigator Completed

Investigators:Alloway 2006 -2008 Roche Pharmaceuticals A randomized, controlled, multi-center trial of oseltamivir versus placebo for the seasonal prophylaxis of influenza in immunocompromised patients Role:Co-Investigator

Investigators:Alloway 2007 -2009 Y's Therapeutics A Controlled, Randomized, Prospective, Double-Blind, Multi-Centre, Phase I/II, Intravenous, Single-Dose, Dose-Escalation Study of the Safety, Pharmacokinetics, and Efficacy of YSPSL for Prevention of Delayed Graft Function in Patients Undergoing Cadaveric Kidney Transplantation Role:Co-Investigator Completed

Investigators:Alloway 2007 -2009 LifeCycle Pharma A/S Phase 2, Open-label Multicenter Prospective, Randomized Trial to Demonstratce the Pharmacokinetics of LCP-Tacro tablets Once daily and Prograf Capsules Twice daily in Adult De Novo Kidney Transplant Patients, the Presence of C2 Epimer Dimer Role:Co-Investigator Completed

Investigators:Alloway 2005 -2009 Isotechnika A phase IIB, randomized, multicenter, open-label, concentration-controlled, safety study of ISA247 and tacrolimus in denovo renal transplant patients Role:PI Completed

Investigators:Alloway 2003 -2009 Wyeth Ayerst Pharmaceuticals A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy Role:Co-Investigator Completed

Investigators:Alloway 2002 -2007 Wyeth-Ayerst Pharmaceutical Company A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients Role:Co-Investigator Completed

Investigators:Alloway 2005 -2009 Roche Laboratories An open label randomized multicenter study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on mycophenolate mofetil and sirolimus without prednisone Role:Co-Investigator Completed

Investigators:Alloway 2005 -2009 Roche Laboratories, Investigator Initiated An open label randomized single center study to evaluate the efficacy and safety of early calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained long-term on mycophenolate mofetil and sirolimus without prednisone Role:Co-Investigator Completed

Investigators:Alloway 2007 -2008 Wyeth Pharmaceuticals A Randomized, Open Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolumus-based Regimen versus Continuation of a Calcineurin Inhibitor-Based Regimen Role:Co-Investigator Completed

Investigators:Alloway 2007 -2009 ViraPharma Incorporated Viropharma CMV A randomized, double blind study to assess the efficacy and safety of prophylactic use of maribavir versus oral ganciclovir for the prevention of cytomegalovirus diseas in recipients of orthotopic liver Role:Co-Investigator Completed

Investigators:Alloway 2005 -2009 Astellas A Phase IV, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Induction Agents Alemtuzumab (Campath 1H®), Basiliximab (Simulect®) or Rabbit Anti-Thymocyte Globulin (Thymoglobulin®) in Combination with Tacrolimus (Prograf®), Mycophenolate Mofetil (Cellcept®) and A Rapid Steroid Withdrawal in Renal Transplant Recipients Role:Co-Investigator Completed

Investigators:Alloway 2007 -2009 LifeCycle Pharma A/S A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day Role:PI Completed

Investigators:Alloway 2007 -2008 Wyeth Pharmaceuticals A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day Role:Co-Investigator Completed

Investigators:Alloway 2007 -2009 Roche Pharmaceuticals A double-blind, randomized, stratified, multi-center trial evaluating conventional and high dose oseltamivir in the treatment of immunocompromised patients with influenza Role:Co-Investigator Completed

Investigators:Alloway 2007 -2009 LifeCycle Pharma A/S A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-Tacro Tablets Once DAILY And Prograf® Capsules Twice DAILY in Adult De Novo Kidney Transplant Patients Role:PI Completed

Investigators:Alloway 2007 -2009 LifeCycle Pharma A/S A Phase 2, Open-Label, Multi-Center, Randomized Trial to Demonstrate the Pharmacokinetics of LCP-TACRO™ Tablets Once Daily and Prograf® Capsules Twice Daily in Adult De Novo Liver Transplant Patients Role:Co-Investigator Completed

Investigators:Alloway 2008 -2010 Covox A single-bead, placebo-controlled, safety and tolerability study of the effects of carbon monoxide for inhalation in patients receiving kidney Role:Co-Investigator Completed

Investigators:Alloway 2003 -2009 NIH Grant Clinical, Immunologic, and Pharmacologic Consequences of Kidney and Liver Transplantation in People with HIV Infection Role:Co-Investigator Completed

Investigators:Alloway 2007 -2009 Integrated Therapeutics Group, Inc Pegylated Interferon alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy Role:Co-Investigator Completed

Investigators:Alloway 2010 -2011 Novartis Pharmaceuticals A prospective, multi-center, open-label, randomized, two period, two sequence, crossover study to compare the steady state pharmacokinetics of generic tacrolimus (Sandoz) to Prograf in stable renal transplant patients Role:PI Completed

Investigators:Alloway 2008 -2011 Wyeth Pharmaceuticals, Now Pfizer Influence of Immunosuppression on the Biologic Behavior of De-novo and Recurrent Cancers in Organ Transplant Recipients Role:Co-Investigator Completed

Investigators:Alloway 2007 -2011 Bristol-Myers Squibb Company A Randomized, Open-Label, Multicenter, Parallel-Group Study of Belatacept-Based Corticosteroid-Free Regimens in Renal Transplant Role:Co-Investigator Completed

Investigators:Alloway 2007 -2010 Genzyme Prospective, Single center, Pilot Feasibility Study Using Thymoglobulin® Preloading in a Rapid Discontinuation of Corticosteroids Protocol in Living Donor Renal Transplantation Using Mycophenolate Mofetil (MMF) and Tacrolimus Maintenance Role:Co-Investigator Completed

Investigators:Alloway 2008 -2010 Bristol-Myers Squibb Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipient Role:Co-Investigator Completed

Investigators:Alloway 2008 -2011 Quark Pharmaceutical Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation Role:Co-Investigator Completed

Investigators:Alloway 2010 -2011 Astellas A Phase 1b, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Dose, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of ASKP1240 in de novo Kidney Transplantation Role:Investigator Completed

Grant: #U01FD004573 Investigators:Alloway, Rita; Kaiser, Tiffany; Sherman, Kenneth; Shields, Adele; Woodle, Ervin Steve 09-15-2012 -09-14-2015 Food and Drug Administration Pharmacokinetic Studies of Tacrolimus in Transplant Patients Role:PI $2,691,189.00 Active Level:Federal

Grant: #HHSF223201310224C Investigators:Alloway, Rita; Kaiser, Tiffany; Shields, Adele 09-26-2013 -09-25-2016 Food and Drug Administration Evaluation of Clinical and Sfety Outcomes Associated with Conversion from Brand-Name to Generic Tacrolimus products in high risk Transplant Recipients Role:PI $2,250,981.00 Awarded Level:Federal

Grant: #500678UC \ UH2AR067688 Investigators:Alloway, Rita; Woodle, Ervin Steve 06-01-2015 -05-31-2017 National Institute of Arthritis, Musculoskeletal and Skin Disease PEARL - Pathway Exploration and Analysis in Renal Lupus Role:Collaborator $126,107.00 Active Level:Federal

Grant: #UCSF PEARL II sub Feinstein Institute sub UH2AR067688 Investigators:Abu Jawdeh, Bassam; Alloway, Rita; Anand, Manish; Tremblay, Simon; Woodle, Ervin Steve 06-01-2018 -05-31-2019 National Institute of Arthritis, Musculoskeletal and Skin Disease Pathway Exploration and Analysis in Renal Lupus (PEARL) – Phase 2 Role:Collaborator $83,271.00 Awarded Level:Federal

Grant: #306067 / R21AI142264 Investigators:Alloway, Rita; Tremblay, Simon; Woodle, Ervin Steve 12-15-2018 -11-30-2020 National Institute of Allergy and Infectious Diseases Single cell analysis of transplant rejection Role:Collaborator $29,553.00 Active Level:Federal

Grant: #S-2744 Investigators:Alloway, Rita; Tremblay, Simon 12-01-2019 -11-30-2020 Dialysis Clinic, Inc. BEST Study - Evaluation of serum belatacept concentrations in renal transplant recipients Role:PI $48,317.00 Awarded Level:Private Non-Profit

Grant: #KPMP / U2CDK114886 Investigators:Alloway, Rita; Tremblay, Simon; Woodle, Ervin 09-01-2019 -08-31-2022 National Inst of Diabetes and Digestive and Kidney Disease Kidney Precision Medicines Project Healthy Living Kidney Donor Tissue Repository Role:Collaborator $100,000.00 Awarded Level:Federal

Publications

Published Abstracts

Winsett RP, Hathaway DK, Alloway RR, Gaber AO (1991. )Effective and Safe Use of Ketoconazole as Adjunctive Immunosuppressive Therapy. .[Abstract]North American Transplant Coordinators Organization, Co-Author

Gaber AO, Kotb M, Winsett RP, Gaber LW, Vera SR, Phillips D, Boskey FD, Alloway RR (1991. )Standard Versus Low Dose OKT3 Induction: Comparison of Immune Monitoring Data and Results. .[Abstract]Proceedings of the American Society of Transplant Physicians, 1-2-32 Co-Author

Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO (1992. )Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function .[Abstract]National Kidney Foundation, Co-Author

Gaber L, Vera S, Hathaway D, Salem A, Alloway RR, Gaber AO (1993. )Routine Biopsy and Induction Therapy Affect Outcome of Delayed Graft Function .[Abstract]American Society of Nephrologists/National Kidney Foundation, Co-Author

Gaber L, Moore L, Alloway RR, Flax S, Gaber AO (1994. )Correlation Between BANFF Classification, Acute Renal Rejection Scores and Reversal of Rejection .[Abstract]American Society of Transplantation Physicians, Co-Author

Alloway RR, Kotb M, Hathaway D, Schroeder T, Gaber AO (1994. )Demographic and clinical factors effecting TCR expression during and following OKT3 treatment .[Abstract]The American Society of Nephrology, Author

Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO (1995. )Ketaconazole enhances loss of bone in renal transplant recipients .[Abstract]American Society of Transplantation Physicians Annual Meeting, Co-Author

Rageuh I, Kotb M, Fraga D, Schroeder T, Chan F, Russell WC, Alloway RR, Gaber AO (05-1995. )A comparison of methodologies used for measurement of circulating OKT3 levels .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Gaber LW, Moore L, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO (05-1995. )Correlation between BANFF scores of acute renal rejection scores and reversal of rejection .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Gaber LW, Moore LW, Alloway RR, Shokouh-Amirir MH, Vera SR, Gaber AO (05-1995. )Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO (08-1995. )Conversion from cyclosporine to FK-506 in kidney, kidney/pancreas and pancreas alone transplant recipients. A single center experience .[Abstract]Minneapolis Transplant Congress: New Immunosuppressive Drugs, Minneapolis, MN,

Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO (08-1995. )Use of FK0506-based immunosuppression in pancreas transplantation .[Abstract]National Association of Transplant Coordinators Organization Annual Meeting, Boston, MA,

Nymann T, Vera SR, Amiri MH, Riely C, Alloway RR, Gaber AO (01-1996. )Prevention of Hepatitis B recurrence with indefinite immunoprophylaxis after liver transplantation .[Abstract]South Eastern Organ Procurement Foundation Tri-Annual Meeting, Orlando, FL,

Gaber LW, Moore LW, Russell W, Alloway RR, Gaber AO (05-1996. )Donor glomerulosclerosis impacts both short- and long-term renal allograft function .[Abstract]American Society of Transplantation Physicians Annual Meeting, Dallas, TX,

Mendez R, Noriega A, Lowance D, Alloway RR, Lee I, Coggon G (03-1997. )Valaciclovir reduces the incidence of CMV disease CMV-seropositive cadaveric renal allograft recipients .[Abstract]Sixth Internatioanl Cytomegalovirus Workshop, Minneapolis, MN,

Alloway RR, Johnson JA, Chaballa M, Russell W, Reed L, Hathaway DK, Amiri H, Vera SR, Gaber AO (05-1997. )Effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients .[Abstract]American Society of Transplantation Surgeons Annual Meeting, Chicago, IL,

Chaballa M, Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO (05-1997. )Five-year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Alloway RR, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO (05-1997. )An open-labeled single center bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Schroeder TJ, First R, Alloway RR, Gaber AO, Levy R, Berger-Moran H, Floch R, Pouletty P (05-1997. )A program to develop cyclosporine formulation that is bioequivalent to Neoral .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ (05-1998. )Preliminary experience with midodrine in kidney/pancreas transplant patients experiencing orthostatic hypotension .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Hurst GC, Somerville KT, Alloway RR, Hathaway D, Moore LW, Gaber AO (05-1998. )Continued loss of bone density one-year post kidney transplant despite preemptive therapy .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Alloway RR, Canafax D, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO (05-1998. )Bioequivalence of Snag-25 and Neoral for cyclosporine metabolites in stable renal transplant patients .[Abstract]American Society of Transplantation Physicians Annual Meeting, Chicago, IL,

Regan J, Alloway RR, Rossi S, Campbell K, Buelow R, Lankford M, Gaber AO (07-1998. )Clinical monitoring of cyclosporine: Capillary whole blood collected with the cyclostat collection device .[Abstract]XVII World Congress of the International Transplant Society, Montreal, Canada,

Gaber AO, Shoukouh-Amiri MH, Stratta RJ, Reddy KS, Alloway RR, Britt LG (12-1998. )Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction .[Abstract]Southern Surgical Association Annual Meeting,

Abell TL, Horn J, Adl D, Self T, Soberman J, Alloway RR, Thompson L (04-1999. )Correlation of cisapride levels with EKG changes: A pilot clinical observation .[Abstract]Digestive Diseases Week Meeting of the American Gastroenterology Association,

Sollinger HW, Bruce D, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ (05-1999. )Multicenter retrospective analysis of simultaneous kidney pancreas transplant recipients receiving Daclizumab induction .[Abstract]18th Annual Meeting of the American Society of Transplantation, Chicago, IL,

Egidi MF, Trofe J, Reed L, Gaber LW, Alloway RR, Shoukouh-Amiri MH, Stratta RJ, Gaber AO (05-1999. )Risk factors for polyoma virus: A comparative analysis in kidney-pancreas and kidney transplants .[Abstract]18th Annual Meeting of the American Society of Transplantation, Chicago, IL,

Trofe J, Alloway RR, Godkin J, Kano J, Stratta RJ, Gaber AO (05-1999. )Thymoglobulin for the prophylaxis or treatment of rejection in pancreas allograft recipients: Results of the US compassionate use experience .[Abstract]18th Annual Meeting of the American Society of Transplantation, Chicago, IL,

Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO (08-1999. )Graft failure after solitary pancreas transplantation .[Abstract]7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia,

Stratta RJ, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS, Gaber AO (08-1999. )Patterns of graft loss after simultaneous kidney-pancreas transplantation according to technique and immunosuppressive era .[Abstract]7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia,

Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Gaber LW, Alloway RR, Hathaway DK, Reddy KS (08-1999. )A single center experience with 108 cases of pancreas transplantation with portal-enteric drainage .[Abstract]7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia,

Sollinger HW, Bruce DS, Humar A, Sutherland DER, Light JA, Kaufman DB, Anderson TK, Alloway RR, Stratta RJ (08-1999. )Multicenter analysis of Daclizumab induction in simultaneous kidney pancreas transplant recipients .[Abstract]7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia,

Stratta RJ, Allwoay RR, Hodge E (05-2000. )An open-label, comparative trial of two Daclizumab dosing strategies versus no antibody induction combined with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney/pancreas recipients: Interim analysis .[Abstract]First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL,

Gaber LW, Lo A, Egidi MF, Stratta RJ, Amiri MH, Grewal HP, Kizilisik T, Alloway RR, Gaber AO (05-2000. )Relationship of histological and clinical features of first acute rejection on recurrent rejection and pancreas failure .[Abstract]First Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL,

Beebe TM, Buell JF, Alloway RR, Hanaway MJ, First MR, Woodle ES (2001. )Donor transmission of a renal cell carcinoma from a living related donor to a kidney recipient .[Abstract]International Transplant Nurses Society,

Aull MJ, Trofe J, First MR, Hanaway M, Beebe TM, Alloway RR, Woodle ES, Buell JF (2001. )Maltoma: infectious etiology of malignancy in transplant patients .[Abstract]International Transplant Nurses Society,

Merchen T, Gupta M, First MR, Trofe J, Gross TG, Bebe TM, Alloway RR, Muthiah C, Hanaway MG, Buells JF, Woodle ES (2003. )PTLD following lung transplantation .[Abstract]American Transplant Congress, Washington, D.C.,

Peer Reviewed Publications

Kelso TM, Alloway RR, Self TH (1992. )Asthma Patient Education .Journal of Pharmacy Practice, ,5 ,186-196

Alloway RR, Kotb M, Gaber L, Boskey F, Gaber AO (1992. )Standard versus Low Dose OKT3 Induction of Cadaveric Renal Transplants: Compairson of Outcome Data versus OKT3 Dose and Serum LEvels .Clin Transplantation, ,46 ,468-472

Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO (1992. )Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients .Scientia, ,1 (6 ),

Self T, Heilker G, Alloway RR, Kelso T, Abou-Shala N (1993. )Reassessing the Therapeutic Range for Theophyilline on Laboratory Report Forms: The Importance of 5-15 mcg/ml .Pharmacotherapy, ,13 (6 ),590-594

Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO (1993. )Results of Prospective, Randomized Double-Blind Study Comparing Standard Versus Low Dose OKT3 Induction Therapy .Transplant Proc, ,25 (1 ),550-552

Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO (1993. )Results of a Prospective, Randomized, Double-Blind Study Comparing Standard versus Low Dose OKT3 Induction Therapy .American Journal of Kidney Diseases, ,22 (36-43 ),

Self T, Alloway R (09-1993. )Nonsedating Antihistamines .Pharmacy Newsletter, ,

Alloway RR (01-1994. )Spotlight of Heparin Dosing. .Drug Information Update, Allied Pharmacy Management Inc, ,

Alloway RR, Kotb M, Hathaway D, Ohman M, Gaber AO (1994. )Pharmacokinetic Profile of OKT3 in Renal Transplant Recipients Receiving Standard and Low Dose OKT3 for Induction Immunosuppression .Transplantation, ,58 ,249-253

Gaber LW, Moore LW, Alloway RR, Shokouh-Amiri MH, Vera SR, Gaber AO (1995. )Glomerulosclerosis as a determinant of post-transplant function of older donor renal allografts .Transplantation, ,60 ,334-339

Gaber LW, Moore LW, Alloway RR, Flax S, Gaber AO (1995. )Correlation between Banff classification, acute renal rejection scores, and reversal of rejection .Transplant Proc, ,27 ,1019

Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO (1996. )Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation .Clin Transplantation, ,10 ,633-667

Moore LW, Alloway RR, Smith SO, Acchiardio SR, Gaber AO (1996. )Clinical obsevations of metabolic changes occurring in renal transplant recipients receiving ketoconazole .Transplantation, ,61 ,537-541

Self T, Alloway R (1996. )Treatment of Rhinitis .J Am Acad Nurse Pract, ,8 ,135-144

Gaberr LW, Moorle LW, Alloway RR, Flax S, Schroeder T, Amiri H, Gaber AO (1996. )Correlation between BANFF scores of acute renal rejection scores and reversal of rejection .Kidney Int, ,49 ,481-497

Alloway RR, Russell WC, Gaber LW, Amiri MH, Vera SR, Gaber AO (1996. )Conversion from Cyclosporine to tacrolimus in kidney, kidney/pancreas and pancreas alone transplant recipients: the Memphis Experience .Transplant Proc, ,28 ,995-997

Elmer D, Nymann T, Hathaway D, Alloway RR, Gaber AO (1996. )Use of FK-506 immunosuppression in pancreas transplant .J Transplant Coordination, ,6 ,122-127

Gaber LW, Moore LW, Reed L, Russell W, Alloway R, Hathaway D, Shokough-Amiri MH, Gaber AO (1997. )Renal histology with varying FK 506 blood levels .Transplant Proc, ,29 ,186

Alloway RR, Schroeder T, Russell W, Moore L, Burton M, Shah M, Gaber AO (1998. )Bioequivalence comparison of Snadimmune and Neoral versus Sang-35 cyclosporine in kidney transplant recipients .J Am Soc Nephrol, ,8 ,672A

Stratta RJ, Alloway RR (1998. )Pancreas transplantation for diabetes mellitus: A guide to recipient selection and optimum immunosuppression .Biodrugs, ,10 (5 ),347-357

Somerville T, Hurst G, Alloway RR, Gaber AO, Shokouh-Amiri MH, Stratta R (1998. )Superior efficacy of oral gancyclovir over oral acyclovir for cytomegalovirus prophylaxis in kidney-pancreas and pancreas alone recipients .Transplant Proc, ,30 ,1546-1548

Hurst G, Alloway RR, Hathaway D, Somerville T, Hughes T, Gaber AO (1998. )Stabilization of bone mass after renal transplant with preemptive care .Transplant Proc, ,30 ,1327-1328

First MR, Alloway RR, Schroeder TJ (1998. )Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral .Clin Transplantation, ,12 ,518-524

Winsett RP and the Posttransplant Quality of Life Intervention Study Group (1998. )Posttransplant quality of life: a decade of descriptive studies leading to practice interventions .J Transplant Coordination, ,8 ,236-240

Gaston R, Alloway RR, Gaber AO, Schroeder TJ, Irish WD, Canafax DM, First MR (1999. )Pharmacokinetics and safety evaluation of SangCya vs Neoral or Sandimmune in stable retransplant recipients .Transplant Proc, ,31 ,326-327

Alloway RR, Somerville TK (1999. )Transplantation: Solid Organ. Basic Bibliographies .Hospital Pharmacy, ,34 ,379

Alloway RR, Somerville TK (1999. )Transplantation Immunusuppression. Basic Bibliographies. Hospital Pharmacy, ,(34 ),380

Stratta RJ< Gaber AO, Shoukouh-Amiri MH, Reddy S, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway DK (1999. )Evolution in Pancreas Transplantation Techniques: Simultaneous Kidney-Pancreas Transplantation Using Portal-Enteric Drainage Without Antilymphocyte Induction .Ann Surg, ,229 ,701-712

Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Egidi MF, Gaber AO (1999. )Surgical complications after pancreas transplantation with portal-enteric drainage .J Am Coll Surg, ,189 ,305-313

Alloway RR (1999. )Generic immunosuppressant use in solid organ transplantation .Transplant Proc, ,31 ,2S-5S

Stratta RJ, Gaber AO, Shokouh-Amiri MH, Reddy KS, Alloway RR, Egidi MF, Grewal HP, Gaber LW, Hathaway D (1999. )Evolution in pancreas transplantation techniques: simultaneous kidney-pancreas transplantation using portal-enteric drainage without antilymphocyte induction .Ann Surg, ,229 ,709-712

Reddy KS, Stratta RJ, Shokouh-Amiri MH, Alloway RR, Somerville T, Egidi MF, Gaber AO (2000. )Simultaneous kidney-pancreas transplantation without antilymphocyte induction .Ann Surg, ,69 ,49-54

Hurst GC, Alloway RR, Somerville KT, Gaber AO, Stratta RJ (2000. )Preliminary experience with midodrine in kidney/pancreas transplant patients with orthostatic hypotension .Clin Transplant, ,14 ,42-47

Meier-Kriesch HU, Alloway RR, Gaber AO, Canafax D, Kaplan B (1999. )A limited sampling strategy (LSS) for the estimation of 12-hour SangCya and Neoral AUCs in renal transplant recipients .J Clin Pharmacol, ,39 ,166-167

Trofe J, Reddy KS, Stratta RJ, Flax SD, Somerville KT, Alloway RR, Egidi MF, Shokouh-Amiri MH, Gaber AO (2001. )Human granulocytic ehrlichiosis in pancreas transplant recipients .Transplant Infectious Disease , ,3 (1 ),34-39

First MR, Alloway RR, Fisher RA, Pan SH, Lopez R, Renlund D, Schnitzler M, Gaber AO (05-2000. )Generic drug substitution in transplantation: examples from the epic of Cyclosporine development .Dialysis and Transplantation, ,29 (5 ),260-267

Tujeta S, Alloway RR, Johnson JA, Gaber AO (2001. )The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients .Transplantation, ,71 ,1303-1307

Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO (2000. )Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients: A cas control study .Clin Transplantation, ,14 ,572-579

Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Trofe J, Alloway RR, Gaber LW, Gaber AO (2001. )Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus mycophenolate mofetil, and prednisone with ganciclovir prophylaxis .Transplant Infectious Disease , ,3 ,8-15

Stratta RJ, Alloway RR, Hodge E, Lo A for the PIVOT study group (2002. )A multicenter, open-label, comparative trial of two Daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis .Clin Transplant, ,16 (1 ),60-68

Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO (2001. )Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric vs. systemic-bladder drainage .American Journal of Kidney Diseases, ,38 ,132-143

Bruce DS, Sollinger HW, Humar A, Sutherland DER, Light JA, Kaufman DB, Alloway RR, Lo A, Stratta RJ (11-27-2001. )Multicenter Survey of Daclizumab Induction in Simultaneous Kidney-Pancreas Transplant Recipients .Transplantation, ,72 (10 ),1637-1643

Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO (2001. )Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil, and steroids in simultenous kidney-pancreas transplantation .Transpl Int, ,14 (6 ),396-404

Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, Alloway RR, Gaber AO (2001. )Post Transplant Lymphoproliferative Disorders: A Single Center Experience .Transplant Proceedings, ,33 (1-2 ),1838-1839

Hardinger KL, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, Honaker MR, Vera SR, Alloway RR, Gaber LW, Gaber AO (2001. )Renal Allograft Outcomes in African-American versus Caucasian Transplant Recipients in the Tacrolimus Era .Surgery, ,130 ,738-748

Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES (2001. )Transmisison of Donor Cancer into Cardio-Thoracic Transplant Recipients .Surgery, ,130 ,660-668

Winset RP, Stratta RJ, Alloway RR, Wicks MN, Hathaway DK (2001. )Immunusuppressant side effect profile does not differ between organ transplant tupes .Clin Transplant, ,15 (Suppl 6 ),46-50

Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO (2002. )Impact of HCV status in pancreas transplantation: a case controlled study .Clin Transplant, ,16 ,1-9

Honaker MR, Amiri S, Vera SR, Alloway RR, Grewal HP, Hardinger KL, Kizilisik TA, Bagous T, Trofe J, Stratta RJ, Egidi MF, Gaber AO (09-2002. )Evolving experience of HBV prophylaxis in liver transplantation .Transplant Infectious Disease , ,4 (3 ),137-143

Lo A, Stratta RJ, Egidi MF, Kizilizik TA, Amiri MH, Grewal HP, Alloway RR, Trofe J, Gaber AO (2001. )Ganciclovir Prophylaxis for CMV Infection in Simultaneous Kidney-Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate Mofetil, and Prednisone .Transplant Proc, ,33 (1-2 ),1768-1769

Lo A, Stratta RJ, Alloway RR, Egidi MF, Shokouh-Amiri MH, Grewal HP, Gaber LW, Gaber AO (2001. )Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation .Transplant Proc, ,33 (1-2 ),1701-1703

Stratta RJ, Alloway RR, Lo A, Hodge E (2001. )A multicenter trial of two Daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: interim analysis .Transplant Proc, ,33 (1-2 ),1692-1693

Stratta RJ, Gaber AO, Shokouh-Amiri MH, Egidi MF, Grewal HP, Kizilisik AT, Alloway RR, Hathaway DK, Gaber LW (2001. )Nine-year experience with 126 pancreas transplants with portal-enteric drainage .Transplant Proc, ,33 (1-2 ),1687-1688

Lo A, Stratta RJ, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Kizilisik AT, Alloway RR, Gaber LW, Gaber AO (2001. )Outcome of simultaneous kidney-pancreas transplantation in African-American recipients: a case control study .Transplant Proc, ,33 (1-2 ),1675-1677

Lo A, Stratta RJ, Hathaway DK, Egidi MF, Amiri MH, Grewal HP, Winsett RP, Trofe J, Alloway RR, Gaber AO (2001. )Long term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric versus systemic-bladder drainage .Transplant Proc, ,33 (1-2 ),1684-1686

Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RH, Nezakatgoo N, Trofe J, Alloway RR, Gaber AO (2001. )The importance of early prevention of renal dysfunction in liver transplant recipients .Transplant Proc, ,33 (1-2 ),1399-4000

Trofe J, Stratta RJ, Egidi MF, Lo A, Gaber LW, Shokouh-Amiri MH, Grewal HP, Honaker M, hardinger K, Alloway RR, Gaber AO (2002. )Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single center experience .Clin Transplant, ,7 (Suppl 16 ),34-44

Lo A, Stratta RJ, Trofe J, Norwood J, Egidi MF, Shokouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO (2002. )Rhodococcus Equi Pulmonary Infection in a Pancreas Alone Transplant Recipient: Consequence of Intense Immunosuppression .Transplant Infectious Disease , ,4 ,46-51

Lo A, Alloway RR (2002. )Strategies to Reduce Toxicities and Improve Outcomes in Renal Transplant Recipients .Pharmacotherapy, ,22 (3 ),316-328

Buell JF, Trofe J, Hanaway MJ, Rilo H, Alloway RR, Beebe T, First MR, Woodle ES (2001. )Transmission of Donor Cancer into Cardio-Thoracic Transplant Recipients .Surgery, ,130 ,660

Aull MJ, Buell JF, Peddi VR, Trode J, Beebe TM, Hanaway MH, Roy-Chaudhury P, Alloway RR, First MR, Woodle ES; Israel Penn International Transplant Tumor Registry (01-2002. )MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report form the Israel Penn International Transplant Tumor Registry with a review of published literature .Transplantation, ,75 (2 ),225-228

Trofe J, Cavallo TC, First MR, Weiskittel P, Peddi VR, Roy-Chaudhury P, Alloway RR, Safdhar S, Buell JF, Hanaway MJ, Woodle ES (2002. )Polyomavirus in kidney and kidney pancreas transplantation: a defined protocol for immunosuppression reduction and histologc monitoring .Transplant Proc, ,34 (5 ),1788-1789

Honaker MR, Stratta RJ, Lo A, Egidi MF, Amiri S, Grewal HP, Alloway RR, Gaber LW, Hardinger KL, Gaber AO (2002. )Impact of hepatitis C virus status and pancreas transplantation: A case controlled study .Clin Transplant, ,16 (4 ),243-251

Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES (2002. )Immunosuppression and Merkel Cell Cancer .Transplant Proc, ,34 (5 ),1780-1781

Buell JF, Trofe J, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES (2002. )De novo breast cancer in renal transplant recipients .Transplant Proc, ,34 (5 ),1778-1789

Trofe J, Gaber LW, Stratta RJ, Shokouh-Amiri HS, Grewal HP, Vera SR, Reed L, Alloway RR, Lo A, Gaber AO (2003. )Polyomavirus in kidney and kidney-pancreas transplant recipients .Transplant Infectious Disease , ,5 (1 ),21-28

Stratta RJ, Alloway RR, Lo A, Hodge E (2002. )A multicenter trial of two dosing strategies versis no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis .Transplant Proc, ,34 (5 ),1903-1905

Woodle ES, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalil K, Gordon J, Trofe J (2003. )Pathology of polyomavirus nephropathy in renal transplant recipients .Journal of Neurovirology, ,9 (Suppl 2 ),16

Trofe J, Gordon J, Roy-Chaudhury P, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalili K, Woodle ES (2003. )Polyomavirus nephropathy in kidney and kidney-pancreas transplantation .Journal of Neurovirology, ,9 (Suppl 2 ),48

Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators (2003. )Two Dose Daclizumab Regimen Provides Superior Outcomes in Simultaneous Kidney/Pancreas Transplant Recipients: Primary Endpoint Analysis of a Multi-Center Randomized Study .Transplantation, ,75 (8 ),1260-1266

Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker M, Alloway RR, Meibohm B (2003. )The effect of CYP3A5 and MDR1 Polymorphis Expression on Cyclosporine Oral Disposition in Renal Transplant Patients .The Journal of Clinical Pharmacology, ,43 (6 ),

Alloway RR, Isaacs R, Lake K, Hoyer P, First MR, Helderman H, Bunnapradist S, Leichtman A, Bennett W, Tejani A, Takemoto S (2003. )Report of the American Society of Transplantation Conference on Immunosuppressive Drugs and the Use of Generic Immunosuppressants .American Journal of Transplantation, ,10 ,1211-1215

Witherow BA, Roth GS, Carrozza MA, Freyberg RG, Kopke JE, Alloway RR, Buell JF, First MR, Gross TG, Hanaway MJ, Troge J, Woodle ES, Beebe TM (2003. )The Israel Penn International Transplant Tumor Registry .Proc AMIA Sympo, ,1053

Buell JF, Trofe J, Sethuraman G, Hanaway MJ, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES (2003. )Donors with central nervous system malignancies: are they truly safe? .Transplantation, ,76 (2 ),340-343

Trofe J, Beebe TM, Buell JF, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES (2004. )Post-Transplant Malignancies .Progress in Transplantation, ,14 (3 ),193-200

Trofe J, Buell JF, Woodle ES, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG (2004. )Recurrence risk following organ transplantation in patients with a history of Hodgkin's disease or non-Hodgkin's lymphoma .Transplantation, ,78 (7 ),972-977

Trofe J, Roy-Chaudhury P, Gordon J, Mutema G, Cavallo T, Cardi M, Austin J, Goel S, Rogers C, Boardman R, Clippard M, Alloway RR, Alexander JW, Metze T, Goodman H, Hanaway MH, Munda R, Buell JF, Peddi VR, Safdar S, HUang S, Fidler J, Khalili K, Woodle ES (2003. )Early Steroid Cessation/Avoidance Regimens are Associated with a Lower Incidence of Polyoma Virus Nephropathy Compared to Steroid Based Immunosuppression in Kidney Transplant Recipients .Transplantation Review, ,17 (4 ),S52-S53

Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES (2003. )Basic and clinical research in polyomavirus nephropathy .Exp Clin Transplant, ,2 (1 ),162-173

Stratta RJ, Alloway RR, Lo A, Hodge E (2004. )Does surgical techniqu influence outcomes after simultaneous kidney-pancreas transplantation? .Transplant Proceedings, ,36 (4 ),1076-1077

Stratta RJ, Alloway RR, Lo A, Hodge E and PIVOT Investigators (2004. )One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative-dosing regimen of Daclizumab .Transplant Proc, ,36 (4 ),1080-1081

Rogers J, Stratta RJ, Alloway RR, Lo A, Hodge EE and PIVOT Investigators (2004. )African-American Ethnicity is no longer a risk factor for early adverse outcome in simultaneous kidney-pancreas transplant with contemporary immunosuppression .Transplant Proceedings, ,36 (4 ),1055-1057

Stratta RJ, Alloway RR, Hodge E, Lo A, PIVOT Investigators (05-2004. )Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients .Transplant Proc, ,36 (4 ),1082-1083

Reddy KS, Stratta RJ, Alloway RR, Lo A, Hodge EE; PIVOT Study Group (05-2004. )The impact of delayed graft function of the kidney on the pancreas allograft in simultaneous kidney-pancreas transplantation .Transplant Proc, ,36 (4 ),1078-1079

Trofe J, Gordon J, Roy-Chaudhury P, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES (04-2004. )Polyomavirus in Solid Organ Transplantation .Progress in Transplantation, ,14 (2 ),130-140

Rogers C, Alloway RR, Boardman R, Trofe J, Hanaway M, Alexander J, Roy-Chaudhury P, Buell J, Thomas M, Cardi M, Susskind B, Woodle ES (2005. )Global Cardiovascular Risk under Early Steroid Cessation Decreases Progressively in the First Year Post Transplant .Graft, ,7 (1 ),38-39

Trofe J, Buell JH, Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG, Woodle ES (2005. )The Israel Penn International Transplant Tumor Registry experience with 402 renal transplant recipients with post transplant lymphoproliferaitve disorder: Multivariate analysis of risk factors that influence survivial .American Journal of Transplantation, ,5 (4 (pt 1) ),775-780

Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES (2005. )African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression .American Journal of Transplantation, ,5 ,356-365

Alloway RR, Hanaway MF, Trofe J, Boardman R,Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES (2005. )A prospective pilot study of early corticosteroid cessation in high immunologic risk patients: The Cincinnati Experience .Transplant Proc, ,37 ,802-803

Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, Woodle ES, Buell JF (2004. )Experience with 274 cardiac transplant recipients post-transplant lymphoproliferative disorder: A report from the Israel Penn International Transplant Tumor Registry .Transplantation, ,11 ,1676-1682

Rogers CC, Hanaway M, Alloway RR, Alexander JW, Boardman RE, Trofe J, Gupta M, Merchen T, Buell JF, Cardi M, Roy-Chaudhury P, Succop P, Woodle ES (2005. )Corticosteroid avoidance ameliorates lymphocele formation and would healing complications associated with sirolimus therapy .Transplant Proc, ,37 ,795-797

Rogers CC, Alloway RR, Hanaway M, Buell JF, Roy-Chaudhury P, Succop P, Woodle ES (2005. )Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression .Transplant Proc, ,37 ,800-801

Buell JF, Gross T, Alloway RR, Trofe J, Woodle ES (2005. )Central Nervous System Tumors in Donors: Misdiagnosis carries a high morbidity and mortality .Transplant Proc, ,37 ,583-584

Alloway RR, Hanaway MF, Trofe J, Boardman R, Rogers CC, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES (2005. )A prospective pilot study of early corticosteroid elimination under modern immunsuppression in patients at high immunologic risk: The Cincinnati experience .Graft, ,7 (1 ),10-11

Boardman R, Trofe J, Alloway RR, Rogers CC, Roy-Chaudhury P, Cardi M, Buell JF, Hanaway M, Thomas MJ, Alexander JW, Munda R, Woodle ES (2005. )Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis .Transplantation Proceedings, ,37 ,817-818

Buell JF, Papaconstantinou HT, Skalow B, Hanaway MJ, Alloway RR, WOodle ES (2005. )De novo colorectal cancer: Five-year survival is markedly lower in transplant recipients compared to the general population .Transplant Proceedings, ,37 ,960-961

Buell JF, Hanaway MJ, Thomas MJ, Munda R, Alloway RR, First MR, Woodle ES (2005. )Donor kidneys with small renal cell cancers: can they be transplanted? .Transplant Proceedings, ,37 ,581-582

Hanaway MJ, Roy-Chaudhury P, Buell JF, Thomas MJ, Munda R, Alloway RR, Ellison V, Rudich SM, Fisher L, Woodle ES (2005. )Pilot study of early corticosteroid elimination after pancreas transplantation .Transplant Proceedings, ,37 ,1287-1288

Buell JF, Gross TG, Hanaway MH, Trofe J, Muthiak C, First MR, Alloway RR, Woodle ES (2005. )Chemotherapy for PTLD: The Israel Penn International Transplant Tumor Registry Experience .Transplantation Proceedings, ,37 ,956-957

Woodle ES, Alloway RR, Hanaway MJ, Buell JF, Thomas MJ, Roy-Chaudhury P, Trofe J (2005. )Early corticosteroid withdrawal under modern immunosuppression in renal transplantation .Transplantation Proceedings, ,37 ,798-799

Rogers CC, Alloway RR, Boardman R, Trofe J, Hanaway MJ, Alexander JW, Roy-Chaudhury P, Buell JF, Thomas MJ, Susskind D, Woodle ES (2005. )Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation .Transplantation Proceedings, ,37 ,812-813

Buell JF, Hanaway MJ, Thomas MJ, Alloway RR, Woodle ES (2005. )Skin cancer following transplantation: The Israel Penn International Transplant Tumor Registry Experience .Transplantation Proceedings, ,37 ,962-963

Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas MJ, Buell JF, ALexander JW, Roy-Chaudhury P, Succop P, Cardi M, Boardman R, Rogers CC (2005. )Histocompatability testing predicts acute rejection risk in early corticosteroid withdrawal regimens .Transplantation Proceedings, ,37 ,809-811

Alloway RR, Trofe J, Boardman R, Rogers CC, Hanaway MJ, Buell JF, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi M, Woodle ES (2004. )A prospective pilot study of early corticosteroid elimination under modern immunosuppression on patients at high immunologic risk: The Cincinnati experience .Graft, ,7 (1 ),10-11

Papaconstantinou HT, Sklow B, Hanaway MJ, Gross TG, Beebe TM, Trofe J, Alloway RR, Woodle ES, Buell JF (2004. )Characteristics and survival patters of solid organ transplant patients developing de novo colon and rectal cancer .Dis Colon Rectum, ,47 (11 ),1898-1903

Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES (2005. )United network for organ sharing publication on scientific registry of Transplant Recipients Central Nervous System Donor Cancer Transmission Data .Transplantation, ,79 (5 ),623

Boardman RE, Alexander JW, Alloway RR, Buell JF, Clippard M, Gupta M, Hanaway M, Merchen T, Metze T, Munda R, Peddi VR, Rogers CC, Roy-Chaudhury P, Susskind B, Trofe J, Woodle ES (2005. )African American renal transplant recipients benefit from early corticosteroid cessation under modern immunosuppression .Transplantation Proceedings, ,37 ,814-816

Rogers CC, Alloway RR, Buell JF, Boardman R, Aelxander JW, Cardi M, Roy-Chaudhury P, First MR, Succop P, Munda R, Woodle ES (07-15-2005. )Body weight alterations under early coticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression .Transplantation, ,80 (1 ),26-33

Lo A, Stratta RJ, Alloway RR, Hodge EE; PIVOT Study Group (03-2005. )A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation .Transplant Proc, ,37 (2 ),1289-1290

Florman S, Alloway RR, Kalayoglu M, Lake K, Bak T, Klein A, Klintmalm G, Busque S, Brandenhagen D, Lake J, Widemandle K, Fitzsimmons W, First MR (03-2005. )Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen .Transplant Proc, ,37 (2 ),1211-1213

Winsett RP, Arheart K, Stratta RJ, Alloway RR, Wicks MN, Gaber AO, Hathaway DK (09-2004. )Evaluation of an immunosuppressant side effect instrument .Prog Transplant, ,14 (3 ),210-216

Buell JF, Beebe TM, Gross TG, Trofe J, Hanaway MJ, Alloway RR, First MR, Woodle ES (2004. )Donor transmitted malignancies .Ann Transplant, ,9 (1 ),53-56

Rogers J, Stratta RJ, Lo A, Alloway RR (2005. )Inferior late functional and metabolic outcomes in African American simultaneous kidney-pancreas recipients .Transplant Proc, ,37 (8 ),3552-3554

Rogers J, Stratta RJ, Lo A, Alloway RR (10-2005. )Impact of metabolic syndrome on long-term outcomes in simultaneous kidney-pancreas transplantation .Transplant Proc, ,37 (8 ),3549-3551

Stratta RJ, Alloway RR, Lo A, Hodge E (10-2005. )Risk factors and outcomes analyses of a prospective, randomized, multicenter trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients .Transplant Proc, ,37 (8 ),3527-3530

Alexander JW, Metze TJ, Goodman HR, Cardi M, Austin J, GOel S, Safdar S, Huang S, Munda R, Fidler J, Buell JF, Hanaway MJ, Susskind B, Greenburg N, Trofe J, Alloway RR, Woodle ES (2006. )Simultaneous corticosteroid and calcineurin inhibitor minimization .European Society for Organ Transplantation, ,19 ,295-302

Woodle ES, Alloway RR, Succop P. Thomas M, Buell J, Tevar A, Munda R, Roy-Chuadhury P, Cardi M, Trofe J (2005. )Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression .American Journal of Transplantation, ,5 (11 ),2740-2744

Alexander JW, Goodman HR, Alloway RR, Woodle ES (2005. )Can immunonutrients reduce rejection rates in African Americans? .Experimental and Clinical Transplantation, ,2 ,349-350

Buell JF, Thomas GG, Thomas MJ, Neff G, Muthiah C, Alloway RR, Woodle ES (08-2006. )Malignancy in pediatric transplant recipients .Seminars in Pediatric Surgery, ,15 (3 ),179-187

Buell JF, Alloway RR, Woodle ES (10-2006. )How can donors with a previous malignancy be evaluated? .J Hepatol, ,45 (4 ),503-507

Weimert NA, Alloway RR (2008. )Monoclonal antibodies in solid organ transplantation .Pharmaceutical Biotechnology: Fundamentals and Applications, ,365-375

Weimert NA, DeRotte M, Alloway RR, Vinks AA, Woodle ES (2007. )Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications .Ther Drug Monitor, ,29 ,141

Vasilic D, Alloway RR, Furr A, Ashcroft R, Kon M, Banis JC, Barker JH, Woodle ES (2007. )Risk assessment of immunosuppressive therapy in facial transplantation .Plastic and Reconstructive Surgery , ,120 (3 ),657-668

Whitaker I, Guggan EM, Alloway RR, Brown C, McGuire S, Woodle ES, Banis JC, Maldonado C, Barker JH (2008. )Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons .Journal of Plastic, Reconstructive and Aesthetic Surgery , ,61 (5 ),481-492

Rike AH, Mogilishetty G, Alloway RR, Succop P, Roy-Chaudhury P, Cardi M, Kaiser TE, Thomas M, Woodle ES (2008. )Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids .Clinical Transplantation, ,22 (2 ),229-235

Walker JK, Alloway RR, Roy-Chaudhury P, Mogilishetty G, Cardi M, Weimert NA, Rike AH, First MR, Woodle ES (02-15-2006. )A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in HLA identical live donor renal transplantation .Transplantation, ,87 (3 ),408-414

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES (2008. )Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection .Transplantation, ,86 ,1754-1761

Vasilic D, Alloway RR, Barker JH, Furr A, Askcroft R, Banis JC Jr, Kon M, Woodle ES (2007. )Risk assessment of immunosuppressive therapy in facial transplantation .Plast Recontstr Surg, ,120 (3 ),657-668

Weimert NA, Alloway RR (2007. )Renal transplantation in high risk patients .Drugs, ,67 (11 ),1603-1627

Alloway RR, Steinburg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsh J, Martas A, Zaltzman J, Wisemandel K, Fitzsimmons W, First MR (06-27-2007. )Two years postconversion from a prograf-based regimen to a once daily tacrolimus extended-release formulation in stable kidney transplant recipients .Transplantation, ,83 (12 ),1648-1651

Florman S, Alloway RR, Kalayoglu M, Punch J, Bak T, Melancon J, Klintmalm G, Busque S, Charlton M, Lake J, Dhadda S, Wisemandle K, Wirth M, Fitzsimmons W, Holman J, First MR (06-27-2007. )Once daily tacrolimus extended release formulation: experience at 2 years post conversion from a Prograf-based in stable liver transplant recipients .Transplantation, ,83 (12 ),1639-1642

Vasilic D, rteynolds CC, Cunningham M, Furr A, Storey B, Banis JC, Wiggins O, Maldonado C, Alloway RR, Kon M, Barker JH (03-2008. )Plastic surgeon's risk acceptance in facial transplantation .Plast Recontstr Surg, ,121 (3 ),41e-48e

Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA (2008. )Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgey in end-stage renal disease and transplant patients: a pilot study .Clin Transplant, ,22 (3 ),281-291

Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Brown E, Woodle ES (2009. )Proteasome inhibition reduces donor-specific antibody levels .Transplant Proceedings, ,41 (1 ),105-107

Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P (2011. )Proteasome inhibitor therapy for antibody-mediated rejection .Pediatric Transplantation, ,15 (6 ),548-556

Trofe-Clark J, Gabardi S, McDevitt-Potter L, Alloway RR (12-17-2011. )Immunosuppression. Generic Drugs and the FDA .Am J Transplant, ,

Busque S, Cantarovich M, Mulgonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators (12-2011. )The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation .Am J Transplant, ,11 (12 ),2675-2684

Woodle ES, Alloway RR, Girnita A (08-2011. )Proteasome inhibitor treatment of antibody-mediated allograft rejection .Curr Opin Organ Transplant, ,16 (4 ),434-438

Alloway RR, Dupuis R, Gabardi S, Kaiser TE, Taber DJ, Tichy EM, Weimert-Pilch NA; American Society of Transplantation Transplant Pharmacy Community of Practice and the American College of Clinical Pharmacy Immunology/Transplantation Practice and Research Network (08-2011. )Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team .Am J Transplant, ,11 (8 ),1576-1583

van Hooff JP, Alloway RR, Trunecka P, Mourad M (2011. )Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de nove kidney, liver, and heart studies .Clin Transplant, ,25 (1 ),

Gaber AO, Mulgaonkar S, Kahan BD, Woodle ES, Alloway RR, Bajjoka I, Jensik S, Klintmalm GB, Patton PR, Wiseman A, Lipshutz G, Kupiec-Weglinski J, Gaber LW, Katz E, Irish W, Squiers EC, Hemmerich S (07-2011. )YSPSL (rPSGL-Ig) for improvement of early renal allograft function; a double-blind, placebo-controlled, multi-center Phase IIa study .Clin Transplant, ,25 (4 ),523-533

Sadaka B, Alloway RR, Woodle ES (2011. )Clinical and investigational use of proteasome inhibitors for transplant rejection .Expert Opinion on Investigational Drugs, ,20 (11 ),1535-1542

Schmidt N, Alloway RR, Walsh CC, Sadaka B, Wall A, Shields AR, Woodle ES (2012. )Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients .Transplantation, ,

Sadaka B, Alloway RR, Shields AR, Schmidt N, Woodle ES (2012. )Proteasome inhibition for antibody mediated allograft rejection .Seminars in Hematology, ,

Book Chapter

Alloway RR, Holt CH, Sommerville KT (1999 )PSAP III-Solid Organ Transplants Pharmacotherapy Self-Assessment Program, 3rd Edition .(pp. 219-267).

Stratta RJ, Gaber AO, Amiri MH, Reddy S, Egidi MG, Grewal HP, Hathaway DK, Winsett RP, Alloway RR, Gaber LW, Britt LG (1998 )Experience with Portal-Enteric Transplant at the University of Tennessee-Memphis Clinical Transplants .(pp. 230-253).

Alloway RR (2001 )Anti-Rejection Chapter Clinical Pharmacokinetics Pocket Reference, 2nd Edition .

Lo A, Alloway R (2001 )Clinical Trials in Renal Transplantation Up-To-Date .Wellesley, MA,

Lo A, Alloway RR (2003 )Clinical Trials in Renal Transplantation Up-To-Date .Wellesley, MA,

Lo A, Alloway RR (2004 )Clinical Trials in Renal Transplantation Up-To-Date .Wellesley, MA,

Buell JF, Gross TG, Beebe T, Alloway RR, Trofe J, Woodle ES (2004 )Cancer after Renal Transplantation Cancer and the Kidney .

Hanaway MJ, Buelle JF, Trofe J, Beebe TM, Gross TG, Alloway RR, First MR, Woodle ES (2004 )Post-Transplant Malignancies in Pancreas Transplant Recipients Pancreas Transplantation .

Alloway RR (2003 )Clinical Chemistry: Theory, Analysis, Correlation, Fourth Edition Laboratory Evaluation of the Transplant Recipient and Donor, Fourth Edition .St. Louis, MO,Mosby

Woodle ES, Alloway RR, Rike A, Roy-Chaudhury P, Tevar A, Susskind B, Everly J, Mogilishetty G, Brailey P, Govil A, Rudich S, First MR, Alexander JW, Munda R, Cardi M, Arend L (2007 )Corticosteroid Elimination: The Cincinnati Experience Clin Transpl .(pp. 51-60).

Alloway RR, et al (2009 )Clinical Chemistry: Theory, Analysis, Correlation, Fourth Edition Laboratory Evaluation of the Transplant Recipient and Donor, 5th Edition .St. Louis,Mosby

Eckman PM, Thorsgard M, Maurer D, Kim Y, Alloway RR, Woodle ES (2009 )Bortezomib for Refractory Antibody Mediated Cardiac Allograft Rejection Clin Transpl .(pp. 475-478).

Presentations

Invited Presentations

Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Shokouh-Amiri MH, Jones M, Vera SR, Grewal HP, Alloway RR, Gaber AO (08-2000. )Post Transplant Lymphoproliferative Disorders: Single Center Experience .18th Annual International Congress of the Transplantation Society,

Kizilisik TA, Lo A, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, Alloway RR, Trofe J, Gaber AO (08-2000. )Ganciclovir Prophylaxis for CMV Infection in Simultaneous Kidney Pancreas Transplant Recipients Receiving Tacrolimus, Mycophenolate, Mofetil, and Prednisose .18th Annual International Congress of the Transplantation Society,

Hanaway MF, Trofe J, Buell JF, Lo A, Alloway RR, Beebe T, Woodle ES (2001. )Cancer Risk in Liver Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience .Transplantation 2001, Chicago, IL.

Trofe J, Buell JF, Hanaway M, Beebe T, First MR, Alloway RR, Lo A, Rilo H, Woodle ES (2001. )Post-Transplant Lymphoproliferative Disorder in Kidney Transplantation: A 32-year Experience in 405 patients from the Israel Penn Transplant Tumor Registry .Transplantation 2001, Chicago, IL.

Stratta RJ, Alloway RR, Lo A, Hodge E (2001. )Multicenter, Open-Label Comparative Trial of 2 Daclizumab Dosing Strategies vs No Antibody Induction in Combination with Tacrolimus, Mycophenolate Mofetil, and Steroids in Simultaneous Kidney-Pancreas Transplantation: 6 Month Analysis .Transplantation 2001, Chicago, IL.

Alloway R (09-1990. )Current Concepts of FK-506 .Transplant Conference, UT Bowld Hospital.

Alloway R (09-1990. )Current Cholesterol Screenings .Tri Beta, Christian Brothers College, Memphis, TN.

Alloway R (1991. )Individual Chemotherapeutic Agents .University of Tennessee, Memphis, Van Vleet Cancer Center.

Alloway R (04-1991. )The Role of Monoclonal and Polyclonal Antibodies in Transplantation .Upjohn Pharmaceutical Corporation Annual Meeting, Memphis, TN.

Alloway R (06-1992. )The Role of Monoclonal and Polyclonal Antibodies in Transplantation .Upjohn Pharmaceutical Corporation Seminar Annual Meeting, Chicago, IL.

Alloway R (12-1992. )The Role of Monoclonal and Polyclonal Antibodies in Transplantation and Results of a Prospective, Randomized Double-Blind Study Comparing Standard versus Low Dose OKT23 Induction Therapy .Symposium on Transplantation Immunology, Ochsner Clinic, New Orleans, LA.

Alloway R (1993. )Pharmacologic and Pharmacokinetic Comparison of Antifungal Agents .Pfizer Laboratories,

Alloway R (06-1993. )Pharmacologic and Pharmacokinetic Comparison of Antifungal Agents .Arkansas Association of Hospital Pharmacists Annual Convention, Hospital Academy Seminar, Fort Smith, AR.

Alloway R (06-1993. )Over-the-Counter Medications to Avoid in Hypertensive Patients .University of Tennessee Medical Group,

Alloway R (02-1994. )Safe Administration of ATGAM .Tulane University, Transplantation Nursing Staff, Teleconference.

Alloway R (03-1994. )Description of a Traineeship in Immunotherapeutics .Twenty-Fourth Annual Tennessee Society of Hospital Pharmacists Meeting,

Alloway R (08-1994. )Kidney Transplant Case History of CMV Infection .Roundtable Discussion, American College of Pharmacy,

Demographic and Clinical Factors Affecting TCR Expressing During and After OKT3 Treatment (10-1994. )The American Society of Nephrology .

Alloway R (02-1995. )An Overview of Transplantation Activities at the University of Tennessee .Board of Trustees, University of Tennessee.

Alloway R (05-1995. )Clinical Monitoring of OKT3 Therapy in the Transplant Patient .University of Tennessee, College of Pharmacy, Department of Clinical Pharmacy Faculty Research Seminar.

Alloway R (08-1995. )The Use of Tacrolimus in Renal Transplant Recipients .St Mary's Hospital, Renal Transplant Division, Grand Rapids, MI.

Alloway R (1995. )CellCept: A Novel Immunosuppressant for Prevention of Renal Allograft Rejection .Nationwide Teleconference, Hoffman LaRoche, Inc,

Alloway R (11-1995. )The Use of Tacrolimus in Renal Transplant Recipients .Harper Hospital, The Detroit Medical Center, Wayne State University, Detroit, MI.

Alloway R (03-1996. )Pharmaceutical care of the Transplant Patient .The Tennessee Society of Home Care, Nashville, TN.

Alloway R (05-1996. )Immunosuppressive Management of the Transplant Patient .Medshares Home Care Company Regional Meetin,

Alloway R (06-1996. )Focusing on Nursing Involvement in Multidisciplinary Research .Twenty-Seventh Annual National Research Development Conference, Memphis, TN.

Alloway R (11-1996. )Pharmaceuticals in Transplantation .United Resources Networks, A Course in Transplantation for Case Managers, Phoenix, AZ.

Alloway R (04-1997. )Immunosuppressive Therapy of the Liver Transplant Patient .University of Tennessee, Division of Gastroenterology, Pathophysiology Conference, Memphis, TN.

Alloway R (04-1997. )New Advances in Immunosuppressive Therapy in the Transplant Patient .University of Tennessee, Division of Endocrinology, Interhospital Grand Rounds, Memphis, TN.

Alloway R (06-1997. )An Open-Labeled Single Center Bioequivalence Comparison of Sandimmune and Noral versus Sang-35 Cyclosporine .Clinical Transplant Pharmacists Advisory Meeting, Seattle, WA.

Alloway R (06-1997. )Effect of Gut Metabolism on Tacrolimus Bioavailability in Renal Transplant Recipients .Clinical Transplant Pharmacists Advisory Meeting, Seattle, WA.

Alloway R (07-1997. )Immunosuppressive Philosophy and Management of the Transplant Patient .Ortho Biotech, National Sales Specialist Training School, Newark, NJ.

Alloway R (09-1997. )Immunosuppressive Management of the Transplant Patient .UT Bowld Hospital Transplant Course,

Alloway R (10-1997. )Immunosuppressive Philosophy and Management of the Transplant Patient .Fujisawa, National Sales Specialist Training School, Deerfield, IL.

Alloway R (11-1997. )Results of US Trials with Generic Cyclosporine in Renal Transplant Recipients .American Society of Nephrology Annual Meeting, Satellite Symposium.

Alloway R (12-1997. )Generic Immunosuppressants: A good idea or not? .1997 American Society of Health System Pharmacists, Satellite Symposium.

Alloway R (12-1997. )Transplant Immunosuppression in 1998: State of the Art, Antibody Therapy in Transplantation .1997 American Society of Health System Pharmacists, Satellite Symposium.

Alloway R (03-1994. )An Overview of Monoclonal and Polyclonal Antibody Therapy and its monitoring .LeBonheur Children's Hospital, Nephrology and Gastroenterology Conference,

Alloway R (02-1998. )Overview of Immunosuppression in Transplantation, Zenapax Use in Transplantation .Nova Factor, Zenapax Project Group, Memphis, TN.

Alloway R (04-1998. )Bioequivalence of cyclosporine and metabolites between Sang-35 and Neoral .Sangstat Medical Corporation National Sales Specialist Training School, Palo Alto, CA.

Alloway R (09-1998. )The clinical development of Sang35 .University of Chicago Transplant Division, Chicago, IL.

Alloway R (09-1998. )An update on antibody therapy in transplantation .University of Chicago Transplant Division, Chicago, IL.

Alloway R (11-1998. )Update on cyclosporine pharmacokinetics and formulations .Midwestern University, Chicago College of Pharmacy, Chicago, IL.

Alloway R (11-1998. )An update on new immunosuppressive agents .1998 Annual Meeting, American College of Clinical Pharmacy, Cincinnati, OH.

Alloway R (11-1998. )Immunosuppressive Philosophy and Management of the Transplant Patient .Fujisawa, National Sales Specialist Training School, Deerfield, IL.

Alloway R (02-1999. )The Development of SangCyA, a Generic Cyclosporine .LeBonheur Children's Hospital, Memphis, TN.

Alloway R (03-1999. )The Development of SangCyA, a Generic Cyclosporine .St. Jude's Children's Research Hospital, Memphis, TN.

Alloway R (03-1999. )Immunology Overview and Immunosuppression .Barnes Jewish Hospital Grand Rounds, St. Louis, MO.

Alloway R (03-1999. )Critical Drugs in Transplantation: Methods of Evaluation. Determination of Therapeutic Equivalence: The Pharmacist's Perspective .1999 Annual APhA Meeting, Satellite Symposium, San Antonio, TX.

Alloway R (04-1999. )TOR Inhibitors: A New Approach to Immunosuppression. Review of the Clinical Trials: Efficacy and Safety. Moderator and Speaker .American College of Clinical Pharmacy, International Congress on Clinical Pharmacy, Satellite Symposium, Orlando, FL.

Alloway R (04-1999. )Bioequivalence Testing of SangCya and Neoral in Stable Renal Transplant Recipients .National Conference, SangStat Medical Corporation,

Alloway R (05-1999. )Immunosuppressive Philosophy and Management of the Transplant Patient .Fujisawa, National Sales Specialist Training School, Deerfield, IL.

Alloway R (05-1999. )The Development of Thymoglobulin for use in Transplantation .LeBonheur Children's Hospital, Memphis, TN.

Alloway R (08-1999. )Development of Generic Immunosuppressants .International Transplant Nurses Society, Toronto, Ontario.

Alloway R (08-1999. )Update on Current Immunosuppressive Therapies .Medimmune Training Course, Gaithersberg, Maryland.

Alloway R (09-1999. )Pancreas Transplantation and Subsequent Challenges .Memphis Area Society for Parenteral and Enteral Nutrition, Memphis, TN.

Alloway R (09-1999. )Pharmacists Opportunities for Collaborative Research in Transplantation .University of Memphis and University of Tennessee, Graduate Program in Health Science Administration Program, Memphis, TN.

Alloway R (10-1999. )Generic Drug Development: Is it Adequate for Immunosuppressants .International Transplant Nurses Society, Birmingham, AL.

Alloway R (10-1999. )Current Status of Immunosuppressive Drug Development in Transplantation .Wichita, Kansas Medical Center Transplant Grand Rounds, Wichita, Kansas.

Alloway R (10-1999. )Current Status of Immunosuppressive Drug Development in Transplantation .University of Vanderbilt Transplant Grand Rounds, Nashville, TN.

Alloway R (11-1999. )The Use of Cyclosporine Generic Derivatives in Adult Transplant Solid Organ Recipients: Implications for Pediatric Transplantation .University of Pittsburgh Children's Hospital Transplant Grand Rounds, Pittsburgh, PA.

Alloway R (12-1999. )Update on New Immunosuppressive Therapies. Breaking Issues .Section of Clinical Specialists of the American Society of Health-System Pharmacists, Orlando, Fl.

Alloway R (01-2000. )The Future of Generic Immunosuppressive Drug Development in Transplantation .University of Utah Transplant Grand Rounds, Salt Lake City, Utah.

Alloway R (01-2000. )Immunosuppressive Drug Therapy in Transplantation .University of Utah Pharamcy Services, Salt Lake City, Utah.

Alloway R (01-2000. )Generic Immunosuppressive Drug Therapy .Austin Diagnostic Clinic Transplant Grand Rounds, Austin, TX.

Alloway R (01-2000. )Overview of Generic Drug Development .Hospital and Managed Care Pharmacy Group of San Antonio, San Antonio, TX.

Alloway R (01-2000. )Generic Immunosuppressive Drug Development in Transplantaion .Cincinnati Children's Medical Center, Cincinnati, OH.

Alloway R (02-2000. )Cyclosporine Generic Derivatives: Use and Misuse Transplantation .Christ Hospital Transplant Grand Rounds, Cincinnati, OH.

Alloway R (02-2000. )Principals and Practice of Generic Drug Development in Solid Organ Transplantation .University of Cincinnati Transplant Seminar, Cincinnati, OH.

Alloway R (02-2000. )Development of Sang-35, a Generic Cyclosporine .Formulary Review Committee, University of Florida, Gainesville, FL.

Alloway R (02-2000. )Generic Drugs in Transplantation .Pharmacists Training Seminar, Abbott Laboratories, Dallas, TX.

Alloway R (02-2000. )Cyclosporine Generic Drug Development .Transplant Grand Rounds, Ochsner Medical Foundation, New Orleans, LA.

Alloway R (03-2000. )Are FDA Guidelines Adequate for Development of Generic Immunosuppressants? .Transplant Grand Rounds, University of Michigan, Ann Arbor, MI.

Alloway R (04-2000. )Transplant 2005 .Annual American Nephrology Nurses Association Meeting, Nashville, TN.

Alloway R (04-2000. )Update on Immunosuppressive Therapy: A Pharmacist's Perspective .Memphis Area Pharmacist Society, Memphis, TN.

Alloway R (04-2000. )Generic Immunosuppressant Use in Transplantation .United Network for Organ Sharing Annual Meeting, Baltimore, MD.

Alloway R (04-2000. )Generic Drugs in Transplantation .Physician's Training Seminar, Abbott Laboratories, Dallas, TX.

Alloway R (04-2000. )The Clinical Relevance of Bioequivalence .Transplant Advisory Meeting, Abbott/SangStat, Vancouver, British Columbia.

Alloway R (05-2000. )Update on Immunosuppressive Therapy for the Transplant Coordinator .Kansas City Transplant Coordinators Annual Meeting, Kansas City, MO.

Alloway R (06-2000. )The Clinical Relevance of Bioequivalence and the Impact of Cyclosporine Generics .Transplant Grand Rounds, Emory University, Atlanta, GA.

Alloway R (07-2000. )Transplant Pharmacology .Transplant Fellows Conference 2000, Vail, CO.

Alloway R (07-2000. )Update on Immunosuppressive Therapy and the Impact on the Development of CMV .Medimmune Training Course, Baltimore, MD.

Alloway R (10-2000. )Transplant 2005 .ITNS Golden Triangle Chapter Meeting, Pittsburgh, PA.

Alloway R (11-2000. )Gengraf Transplant Patient Data Overview .Virginia Formulary, Richmond, Virginia.

Alloway R (01-2001. )Transplant, Past, Present and Future. Maximizing the Pharmacist's Role in Transplant Patient Management: Current Best Practices .Marco Island, FL,

Alloway R (02-2001. )The Scientific Data on Cyclosporine Generics: Pharmacokinetics .American Society of Transplantation, St. Louis, MO.

Alloway R (04-2001. )The Clinical Impact of Gut Transport and Metabolism on Drug Availability: An Example of Tacrolimus .University of Cincinnati, Division of Nephrology and Hypertension Research Conference, Cincinnati, OH.

Alloway R (04-2001. )The Clinical Impact of Gut Transport and Metabolism on Drug Availability: An Example of Tacrolimus .University of Cincinnati, Department of Pharmacy Grand Rounds, Cincinnati, OH.

Alloway R (10-2001. )Trials and Tribulations of Clinical Research .University of Cincinnati, Division of Nephrology and Hypertension Research Conference, Cincinnati, OH.

Alloway R (11-2001. )State of the Art of Corticosteroid Elimination in Kidney Transplantation Immunosuppressive Regimens .University of Cincinnati, Department of Internal Medicine, Departmental Research Conference, Cincinnati, OH.

Alloway R (03-2002. )Understanding Generic Drug Development: The Relationship to Cyclosporine, Modified Products .Dallas Transplant Institute Grand Rounds, Dallas, TX.

Alloway R (06-2002. )Understanding Generic Drug Development: The Relationship to Cyclosporine, Modified Products .Boston Transplant Society, Boston, MA.

Alloway R (06-2002. )Understanding Generic Drug Development: The Relationship to Cyclosporine, Modified Products .Visiting Professors from Poland, Cincinnati, OH.

Alloway R (10-2002. )CellCept Current Status in Transplantation .Current Issues in Transplantation, Albuquerque, NM.

Alloway R (10-2002. )Calcineurin Inhibitor and Steroid Sparing Protocols: Who, When and How .Building a Treatment Strategy for Long-Term Transplant Patient Care, Albuquerque, NM.

Alloway R (11-2002. )Sirolimus as Part of Steroid and Calcineurin Inhibitor Minimization and Withdrawal Regimens .University of Vancouver, Vancouver, British Columbia.

Alloway R (11-2002. )Sirolimus as Part of Steroid and Calcineurin Inhibitor Minimization and Withdrawal Regimens .University of Edmonton, Edmonton, Alberta.

Alloway R (11-2002. )Sirolimus as Part of Steroid and Calcineurin Inhibitor Minimization and Withdrawal Regimens .University of Calgary, Calgary, Alberta.

Alloway R (12-2002. )Thymoglobulin Induction as Part of Steroid and Calcineurin Inhibitor Minimization and Withdrawal Regimens .Atlanta, GA.

Alloway R (03-2003. )Development of FKMR: Modified Release Tacrolimus .University of Cincinnati, Division of Nephrology and Hypertension Research Conference, Cincinnati, OH.

Alloway R (04-2003. )The Clinical Impact of Gut Transport and Metabolism on Drug Availability: An Example of Tacrolimus .University of Cincinnati, Department of Surgery Research Conference, Cincinnati, OH.

Alloway R (04-2003. )The Clinical Impact of Gut Transport and Metabolism on Drug Availability: An Example of Tacrolimus .University of Cincinnati, Department of Internal Medicine Grand Rounds, Cincinnati, OH.

Alloway R (04-2003. )Understanding Generic Drug Development: The Relationship to Cyclosporine, Modified Products .University of Florida, Gainesville, FL.

Alloway R (04-2003. )Understanding Generic Drug Development: The Relationship to Cyclosporine, Modified Products .University of Tampa, Tampa, FL.

Alloway R (10-2003. )Steroid Sparing Protocols: State of the Art .International Transplant Nurses Society, Scottsdale, AZ.

Alloway R (03-2004. )Trials and Tribulations of Clinical Research .Thomas Jefferson University Transplant Grand Rounds, Philadelphia, PA.

Alloway R (03-2004. )Steroid Sparing Protocols: State of the Art .Transplant Grand Rounds, Philadelphia, PA.

Alloway R (03-2004. )Managing the Side Effects of Sirolimus .Wyeth 4th International Transplantation Symposium, Seville, Spain.

Alloway R (03-2004. )Trials and Tribulations of Clinical Research .University of Alabama Transplant Grand Rounds, Birmingham, AL.

Alloway R (06-2004. )Steroid Sparing Protocols: State of the Art .Fujisawa Clinical Pharmacy Advisory Board, Broadmoor, CO.

Alloway R (10-2004. )Corticosteroid Minimization: Current State of the Art .International Transplant Nurses Society, Vancouver, British Columbia.

Alloway R (10-2004. )Steroid Elimination Under Thymoglobulin Induction .Genzyme Pharmacy Advisory Board, Dallas, TX.

Alloway R (10-2004. )Practice Updates in Solid Organ Transplantation .American College of Clinical Pharmacists, Dallas, TX.

Alloway R (11-2004. )Corticosteroid Elimination: The University of Cincinnati Experience .Transplant Grand Rounds, Medical College of South Carolina, Charleston, SC.

Alloway R (03-2005. )Managing the Adverse Effects of Sirolimus .Panel Discussion, Wyeth 5th International Symposium, Athens, Greece.

Alloway R (02-2005. )A Single Center Pilot Study to Determine the Pharmacokinetics of Various Immunosuppressants in Transplant Recipients Who Have Undergone Gastric Bypass Surgery .Nephrology Grand Rounds, University of Cincinnati, Cincinnati, OH.

Alloway R (04-2005. )Investigational Immunosuppressants .University of Cincinnati Transplant Lecture Series, Cincinnati, OH.

Alloway R (05-04-2005. )Pharmacist Involvement in Transplantation .Consultant, Yale University School of Medicine, New Haven, CT.

Alloway R (09-09-2005. )How to Design Clinical Trials: How to Estimate and Negotiate the Study Budget .American Society of Transplantation Clinical Trials Symposium: Study Design and Endpoints, Chicago, IL.

Alloway R (01-2006. )How to Design Clinical Trials: How to Estimate and Negotiate the Study Budget .American Society of Transplant Surgeons / National Transplant Coordinators Organization Winter Symposium, Arizona.

Alloway R (09-29-2009. )How to Design Clinical Trials: How to Estimate and Negotiate the Study Budget .American Transplant Society of Transplantation Clinical Trials Symposium: Study Design and Endpoints, Chicago, IL.

Alloway R (03-2007. )How to Estimate and NEgotiate the Study Budget .Canadian Transplant Society, Banff, Alberta, Canada.

Alloway R (06-2007. )Corticosteroid Elimination: University of Cincinnati Experience .Piedmont Transplant Program, Atlanta, GA.

Alloway R (07-2007. )FKXL Data Review .Transplant Advisory Board Meetings, Portland, OR; Chicago, IL; Boston, MA.

Alloway R (06-19-2008. )The Impact of Generics on Transplantation .Novartis Advisory Board, Chicago, IL.

Alloway R (11-19-2008. )The Impact of Generics on Transplantation .Transplant Team Lecture, Fort Wayne, IN.

Alloway R (12-15-2005. )Trials and Tribulations of Clinical Research: An Organizational and Budgetary Perspective .Transplant Grand Rounds, University of Iowa, Iowa City, IA.

Alloway R (12-15-2008. )A Pharmacists Role as Director of Transplant Clinical Research .College of Pharmacy Grand Rounds, University of Iowa, Iowa City, IA.

Alloway R (06-03-2009. )Testing of Generic Drugs in Transplantation: Are they Equivalent? .Moderator, American Transplant Congress Workshop, Boston, MA.

Alloway R (07-07-2009. )Generic Immunosuppressants in Transplantation. Are They Equivalent? .University of Cincinnati Transplantation Grand Rounds, Cincinnati, OH.

Alloway R (12-2009. )Generic Drugs: Good Medicine or Cheap Fix? .University of Cincinnati Department of Internal Grand Rounds, Cincinnati, OH.

Alloway R (05-2010. )Generic Drugs: Good Medicine or Cheap Fix? .American Transplant Congress Workshop, San Diego, CA.

Alloway R (03-2011. )Generic Drugs: Good Medicine or Cheap Fix? Comparison of Regulatory Guidelines .Pfizer Canadian Transplant Advisory Board, Montreal, Quebec.

Alloway R (05-2011. )Clinical Study Implementation and Management: Operational Issues .American Transplant Congress, Clinical Trials Symposium,

Alloway R (11-2011. )Use of Clinical Pharmacology in Trial Design to Identify the Optimum Dose .FDA Workshop: Ischemia Reperfusion Injury and Downstream Effects of Delayed Graft Function, Other Short Term and Long Term Outcomes in Kidney Transplantation, Washington, D.C..

Alloway R (09-2011. )Overview of Proteasome Inhibitor Based Antihumoral Therapies Program. HLA Antibodies from the Laboratory in the Clinical Floor .New Jersey Organ and Tissue Sharing Program, New Providence, New Jersey.

Poster Presentations

Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RJ, Khan NA, Trofe J, Alloway RR, Gaber AO (08-2000. )The Importance of Early Prevention of Renal Dysfunction in Liver Transplant Recipients .18th Annual International Congress of the Transplantation Society,

Hardinger KL, Stratta RJ, Egidi MF, Alloway RR, Amiri MH, Gaber LW, Grewal HP, Honaker MR, Vera SR, Gaber AO (2001. )Renal Allograft Outcomes in African American versus Caucasian Transplant Recipients in the Tacrolimus Era .Transplantation 2001, Chicago, IL. .

Trofe J, Stratta RJ, Lo A, Gaber LW, Amiri HS, Grewal HP, Egidi MF, Honaker M, Hardinger K, Alloway RR, Gaver AO (2001. )Thymoglobulin for induction or rejection therapy in pancreas allograft recipients-single center experience .Transplantation 2001, Chicago, IL. .

Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, Woodle ES, Buell JF (02-2001. )PTLD in cardiac transplantation: A report on 274 patients from the Israel Penn International Tumor Transplant Registry experience of post transplant lymphoproliferative disorder in kidney transplantation .Third International Symposium on Immunodeficiencies, Berlin, Germany. .

Alexander JW, Metze TJ, Goodman HR, First MR, Cardi MA, Safdhar S, Mendoza NC, Munda R, Fidler JP, Alloway RR, Buell JF, Hanaway MJ, Greenburg NA, Woodle ES (2002. )Simultaneous Corticosteroid Avoidance and Minimization of Calcineurin Inhibitors .American Transplant Congress, Washington, DC. .

Trofe J, Cavallo T, First MR, Roy-Chaudhury P, Peffi R, Weiskittel P, Bryant M, Brown S, Khalili K, Gordon J, Alloway RR, Hanaway MJ, Buell JF, Woodle ES (2002. )Polyomavirus in Kidney/Kidney-Pancreas Transplantation: Minimizing Renal Allograft Injury/Loss by Defined Immunosuppression Reduction and Histologic Monitoring .American Transplant Congress, Washington, DC. .

Peddi VR, Govil A, Weiskittle P, Alloway RR, Goel S, Woodle ES, First MR (2002. )Long-Term Follow-Up of Sirolimus Substitution for Calcineurin-Inhibitors in Kidney and Kidney/Pancreas Allograft Recipients with Nephrotoxicity .American Transplant Congress, Washington, DC. .

Peddi VR, Brown S, Hanaway MJ, Buell JH, Alloway RR, Munda R, Woodle ES, First MR (2002. )Efficacy and Cost-Analysis of Thymoglobulin (TMG) Induction with Intermittent Dosine Based on CD3+ Lymphocyte Counts in Pancreas Transplant Recipients .American Transplant Congress, Washington, DC. .

Woodle ES, Hanaway MJ, Buell JF, Brown S, Alloway RR, Peddi VR, D'Alessio D, Rilo HR (2002. )Hypoglycemia Unawareness and Diabetes-Related Morbidity in Islet Transplant Candidates .American Transplant Congress, Washington, DC. .

Hanaway MF, Rilo H, Brown S, Peddi VR, Buell JF, Alloway RR, D'Alessio D, Woodle ES (2002. )Hypoglycemic Unawareness: Characterization of Severity in Islet Transplant Candidates .American Transplant Congress, Washington, DC. .

Rilo H, Upshaw L, Hanaway M, Brown S, Fredrickson L, Burke B, D'Alessio D, Woodle ES (2002. )Continuous Glucose Monitoring (CGM): A Potential Objective Means for Determination of Candidacy for Islet Transplantation .American Transplant Congress, Washington, DC. .

Trofe J, Sethuraman G, Buell JF, Hanaway MJ, First MR, Alloway RR, Gross TG, Beebe TM, Woodle ES (2002. )Multivariate Analysis of Risk Factors That Influence Survival in Renal Transplant Recipients with PTLD .American Transplant Congress, Washington, DC. .

Trofe J, Buell JF, First MR, Beebe T, Aull MJ, Gross TG, Hanaway MJ, Alloway RR, Woodle ES (2002. )Renal Allograft Involvement by Post Transplant Lymphoproliferative Disorder: Clinical Implications .American Transplant Congress, Washington, DC. .

Woodle ES, Buell JF, Hanaway MJ, Beebe T, Peddi VR, Alloway RR, First MR, Trofe J (2002. )Biologic Behavior of Carcinoid Tumors on Solid Organ Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience .American Transplant Congress, Washington, DC. .

Buell JF, Hanaway MJ, Trofe J, Alloway RR, Beebe T, Gross T, First MR, Woodle ES (2002. )De Novo Sarcomas: In Solid Organ Transplant Recipients .American Transplant Congress, Washington, DC. .

Aull MJ, Buell JF, Gross TG, Trofe J, Alloway RR, Beebe TM, Hanaway MJ, First MR, Woodle ES (2002. )Transplantation in Patients with Pre-Exisiting Leukemias .American Transplant Congress, Washington, DC. .

Aull MJ, Buell JF, Gross TG, Trofe J, Alloway RR, Beebe TM, Hanaway MJ, First MR, Woodle ES (2002. )De Novo Leukemias in Solid Organ Transplant Recipients: A Report from the Israel Penn International Transplant Tumor Registry .American Transplant Congress, Washington, DC. .

Buell JF, Hanaway MJ, Trofe J, Alloway RR, Beebe T, Arrand-Michel J, Gross T, First MR, Woodle ES (2002. )Post-Transplant Lymphoproliferative Disorder in Liver Transplant Recipients: Comparison between Children and Adults .American Transplant Congress, Washington, DC. .

Hanaway MJ, Buell JF, James L, Alloway RR, Gross T, Trofe J, Beebe T, First MR, Woodle ES (2002. )PTLD in Pancreas Transplantation: A Mutlicenter Analysis .American Transplant Congress, Washington, DC. .

Woodle ES, Buell JF, Hanaway MF, Trofe J, Aull MJ, Gross T, First MR, Alloway RR, Beebe T (2002. )Kaposi's Sarcoma: Differential Clinical Patterns in U.S. and International Patients .American Transplant Congress, Washington, DC. .

Zavala EY, Rilo HR, Hanaway MJ, Brown SF, Peddi VR, First MR, Martin JE, Alloway RR, Buell JF, Matthews JB, Woodle ES (2002. )An Economic Evaluation of Human Islet Transplantation .American Transplant Congress, Washington, DC. .

Buell JF, Hanaway MJ, Trofe J, Alloway RR, Beebe T, Aranda-Michel J, Gross T, First MR, Woodle ES (2002. )Post-transplant Lymphoproliferative Disorder in Liver Transplant Recipients: Comparison Between Children and Adults .XIX International Congress of Transplant Surgeons, Miami, FL. .

Aull MJ, Buell JF, Gross T, Trofe J, Alloway RR, Beebe T, Hanaway MJ, First MR, Woodle ES (2002. )De Novo Leukemias in Solid Organ Transplant Recipients: A report from the Israel Penn International Transplant Tumor Registry .XIX International Congress of Transplant Surgeons, Miami, FL. .

Aull MJ, Buell JF, Gross T, Trofe J, Alloway RR, Beebe T, Hanaway MJ, First MR, Woodle ES (2002. )Transplantation in Patients with Pre-existing Leukemias .XIX International Congress of Transplant Surgeons, Miami, FL. .

Hanaway MJ, Buell JF, James L, Alloway RR, Gross T, Trofe J, Beebe T, First MR, Woodle ES (2002. )De Novo Cancer after Pancreas Transplantation: The IPITTR Experience .XIX International Congress of Transplant Surgeons, Miami, FL. .

Kelso TM, Self TH, Alloway RR (02-1992. )Cost Benefit of Conversion form Nebulized Therapy to MDI plus Spacer .Practice and Research Forum of the American College of Clinical Pharmacy,

Kelso TM, Self TH, Alloway RR (04-1992. )Cost Benefit of Conversion form Nebulized Therapy to MDI plus Spacer .Tennessee Thoracic Society Annual Meeting,

Alloway RR, Kotb M, Hathaway DK, Vera SR, Britt L< Gaber AO (08-1992. )Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients .International Congress of Transplantation Society,

Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO (05-1992. )Results of a Prospective, Randomized, Double-Blind Study Comparing Standard versus Low Dose OKT3 Induction Therapy .American Society of Transplant Surgeons,

Kotb M, Hathaway DK, Alloway RR, Gaber LW, Docktor M, Vera SR, Gaber AO (05-1993. )Evaluation of Immunological Markers Predictive of Successful OKT3 Induction .American Society of Transplant Physicians Annual Meeting,

Alloway RR, Kotb M, Hathaway DK, Ohman M, Strain S, Gaber AO (05-1993. )Pharmacokinetic Profile of OKT3 in Renal Transplant Recipients Receiving Standard and Low Dose OKT3 for Induction Immunosuppression .American Society of Transplant Physicians,

Ohman M, Kotb M, Leathers LK, Hathaway DK, Alloway RR, Gaber LW, Gaber AO (08-1993. )Multiparameter Monitoring of Efficacy of OKT3-Induced Immune Suppression in renal ALlograft Recipients .19th Annual Meeting of the American Society of Histocompatibility and Immunogenetics, San Francisco, CA. .

Lomas R, Kuns J, Mumar A, Alloway RR, Abell TL (05-1993. )Patient Controlled Promethazine Infusion for Symptom Control in Intractable Nausea and Vomiting .American Gastroenterological Association/American Association for the Study of Liver Diseases,

Gaber L, Moore L, Alloway RR, Flax S, Gaber AO (11-1993. )Clinical Applicability of the BANFF Classification for Acute Renal Rejection .26th Annual Meeting of The American Society of Nephrology,

Gaber L, Moore L, Alloway RR, Amiri H, Gaber AO (11-1993. )Influence of Donor Nephrosclerosis (ANS) on Kidney Allograft Function .26th Annual Meeting of The American Society of Nephrology,

Lomas R, Kuns J, Kumar A, Allowary RR, Voeller G, Abell TL (05-1994. )One-Year Follow Up of Patients Treated with Patient Controlled Promethazine for Intractable Nausea .American Gastroenterological Association/American Association for the Study of Liver Diseases,

Evans SL, Alloway RR, Vera S, Horvath J, Hathaway DK, Gaber AO (05-1995. )The clinical of CMV titers and cultures in the clinical management of transplant patients .American Society of Transplant Physicians Annual Meeting,

Anderson RN, Sherman J, Alloway RR, Solomon SS (05-1997. )Effect of cyclosporine and FK506 on insulin actions in H=411E cells .American Society of Transplantation Physicians, Chicago, IL. .

Alloway RR, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO (11-1997. )Bioequivalence comparison of Sandimmune and Neoral versus Sang-35 cyclosporine in kidney transplant recipients .Annual Scientific Meeting of the American Society of Nephrology, San Antonio, TX. .

Somerville T, Hurst G, Alloway RR, Shokouh-Amiri MH, Gaber A, Stratta R (12-1997. )Superior efficacy of oral gangiclovir over oral acyclovir for CMV prophylaxis in kidney/pancreas and pancreas alone recipients .Seventh International Congress on Immunosuppression, Orlando, FL. .

Chaballa M, Alloway RR, Kotb M, Hathaway DK, Gaber LW, Vera SR, Gaber AO (12-1997. )Five-year followup of a prospective randomized double-blind study comparing standard versus low dose OKT3 induction therapy in renal allograft recipients .Seventh International Congress on Immunosuppression, Orlando, FL. .

Hurst G, Alloway RR, Hathaway D, Somerville T, Moore L, Gaber A (12-1997. )Stabilization of bone mass post-renal transplant with preemptive care .Seventh International Congress on Immunosuppression, Orlando, FL. .

Alak AM, Moy S, Alloway RR, Fraga D, Kotb M, Gaber AO (12-1997. )Tacrolimus concentrations in renal transplant patients: correlation between levels determined by Abbott Imx and HPLC coupled with mass spectrometer .Seventh International Congress on Immunosuppression, Orlando, FL. .

Alloway RR, Schroeder T, Russell W, Reddy K, Moore L, Burton M, Shah, Gaber AO (09-1997. )A bioequivalence crossover study comparison of Sang-35 cyclosporine versus Sandimmune and Neoral in kidney transplant patients .Eight Congress of the European Society for Organ Transplantation, Budapest, Hungary. .

Somerville T, Hurst G, Alloway RR, Shokouh-Amiri MH, Gaber A, Stratta R (05-1998. )Efficacy of oral gancilovir for CMV prophylaxis in kidney/pancreas and pancreas alone recipients .American Society of Transplant Physicians, Chicago, IL. .

Russell W, Alloway RR, Demirkan K, Stratta R, Gaber AO (05-1998. )Preliminary experience with troglitazone (Rezulin) in kidney and kidney/pancreas transplant recipients .American Society of Transplant Physicians, Chicago, IL. .

Reddy KS, Stratta R, Shokouh-Amiri H, Alloway RR, Somerville T, Elmer D, Gaber AO (05-1998. )Simultaneous kidney-pancreas transplantation without antilymphocyte induction .American Society of Transplant Physicians, Chicago, IL. .

Schroeder TJ, First MR, Alloway RR, Canafax DM, Gaber AO, Gaston R (05-1998. )A series of comparative trials between Sang-35 and other cyclosporine formulations in stable renal transplant patients .American Society of Transplant Physicians, Chicago, IL. .

Regan J, Alloway RR, Rossi S, Campbell K, Buelow R, Lankford M, Gaber AO (05-1998. )Clinical monitoring of cyclosporine using capillary blood collected and dried onto a collection device (Cyclostat) .American Society of Transplant Physicians, Chicago, IL. .

Reddy KS, Stratta R, Shokouh-Amiri H, Alloway RR, Somerville T, Elmer D, Gaber AO (07-1998. )Simultaneous kidney-pancreas transplantation without antilymphocyte induction .XVII World Congress, Montreal, Quebec, Canada. .

Somerville T, Reddy S, Alloway RR, Hurst G, Gaber AO, Shokouh-Amiri MH, Stratta R (07-1998. )Incidence and management of mycophenolate mofetil adverse effects in simultaneous kidney/pancreas transplant patients .XVII World Congress, Montreal, Quebec, Canada. .

Schroeder T, First R, Alloway RR, Pan SH, Gaber AO (07-1998. )Pharmacokinetic trials in normals, kidney and liver transplant patients: Sang-35 vs. Neoral cyclosporine .XVII World Congress, Montreal, Quebec, Canada. .

Gaston R, First MR, Alloway RR, Canafax Dm, Gaber AO, Schroeder TJ (07-1998. )Sang-35 vs. Neoral or Sandimmune in stable renal transplant recipients .XVII World Congress, Montreal, Quebec, Canada. .

Meier-Kriesch HU, Alloway RR, Gaber AO, Canafax D, Kaplan B (10-1998. )A limited sampling (LSS) to predict the Sang-35 area under the curve (AUC) in adult renal transplant recipients. .31st Annual Meeting and Scientific Exposition of the American Society of Nephrology, Philadelphia, PA. .

Alloway RR, VanFleet A, Schroeder TJ, Canafax DM, Moore LW, Shah MJ, Gaber AO (10-1998. )A clinical practice experience in the development of Sang-35, a new cyclosporine formulation .31st Annual Meeting and Scientific Exposition of the American Society of Nephrology, Philadelphia, PA. .

Reddy KS, Stratta R, Alloway RR, Somerville T, Amiri HS, Gaber AO (10-1998. )Innovations in Pancreas Transplantation: Simultaneous kidney-pancreas transplant using portal-enteric drainage without anti-lymphocyte induction .31st Annual Meeting and Scientific Exposition of the American Society of Nephrology, Philadelphia, PA. .

Tuteja S, Alloway RR, Johnson JA, Gaber AO (05-1999. )Effect of gut metabolism on tacrolimus (FK-506) bioavailability in renal transplant recipients .18th Annual Meeting of the American Society of Transplantation, Chicago, IL. .

Lo A, Alloway RR, Trofe J, Amiri JS, Egidi MF, Grewal HP, Stratta RJ, Vera S, Gaber AO (05-1999. )Outcomes in solid organ transplant patients received granulocyte stimulating factor (G-CSF) for the management of neutropenia .18th Annual Meeting of the American Society of Transplantation, Chicago, IL. .

Trofe J, Reddy KS, Somerville TK, Egidi MF, Flax M, Alloway RR, Stratta RJ, Gaber AO (05-1999. )Ehrlichiosis after pancreas transplantation .18th Annual Meeting of the American Society of Transplantation, Chicago, IL. .

Gaber L, Egidi MF, Sing V, Trofe J, Alloway RR, Kotb M, Gaber AO (05-1999. )Focal mild intimal arteritis without associated parenchymal inflammation: Rejection of No Rejection .18th Annual Meeting of the American Society of Transplantation, Chicago, IL. .

Stratta RJ, Lo A, Hathaway DK, Winsett RP, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO (05-1999. )Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric drainage .25th Annual Meeting of the American Society of Transplant Surgeons, Chicago, IL. .

Egidi MF, Trofe J, Stratta RJ, Amiri MH, Grewal HP, Alloway RR, Gaber AO (05-1999. )The effect of tacrolimus on the blood sugar control in pancreas transplant patients: A comparison among systemic engteric, portal enteric, and bladder Anastomosis techniques .25th Annual Meeting of the American Society of Transplant Surgeons, Chicago, IL. .

Nguyen BN, Alloway RR, Gaber AO, Johnson JA (05-1999. )Relationship between cyclosporine and endothelin concentrations in renal transplant recipients .18th Annual Meeting of the American Society of Transplantation, Chicago, IL. .

Stratta RJ, Egidi MF, Shokouh-Amiri MH, Grewal HP, Hathaway DK, Alloway RR, Gaber AO (08-1999. )Analysis of mortality after pancreas transplantation according to transplant type and immunosuppressive era .7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia. .

Stratta RJ, Lo A, Hathaway DK, Winsett RP, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO (08-1999. )Is the native pancreas more susceptible to abnormalities causing glucose intolerance than the transplanted pancreas? .7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia. .

Stratta RJ, Lo A, Hathaway DK, Winsett RP, Egidi MF, Shoukouh-Amiri MH, Grewal HP, Alloway RR, Gaber AO (08-1999. )Long-term outcomes in simultaneous kidney-pancreas transplant recipients with portal-enteric drainage .7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia. .

Egidi MF, Trofe J, Stratta RJ, Amiri MH, Grewal HP, Alloway RR, Gaber AO (08-1999. )Glucose control in pancreas transplants: Comparative study among anastomotic techniques .7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia. .

Trofe J, Alloway RR, Godkin J, Kano J, Stratta R, Gaber A (08-1999. )Thymoglobulin use in pancreas transplantation .7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia. .

Trofe J, Reddy KS, Somerville TK, Egidi MF, Flax M, Alloway RR, Stratta RJ, Gaber AO (08-1999. )Ehrlichiosis infection in pancreas transplants .7th World Congress of the International Pancreas and Islet Transplant Association, Sydney, Australia. .

Egidi MF, Trofe J, Reed L, Gaber LW, Alloway RR, Shokouh-Amiri MH, Stratta RJ, Gaber AO (08-1999. )Risk factors for polyoma virus (BK): Comparative analysis in kidney and pancreas transplants .Seventh International Congress on Immunosuppression, Sydney, Australia. .

Egidi MF, Trofe J, Stratta RJ, Flax SD, Gaber LW, Amiri HS, Jones M, Khan NA, Vera SR, Grewal HP, Alloway RR, Gaber AO (05-2000. )Post transplant lymphoproliferative disorders: therapeutic approach and outcome in solid organ transplantation .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Amiri HS, Lo A, Hardinger K, Alloway RR, Trofe J, Grewal HP, Vera SR, Anderson T, Kizilisik T, Gaber AO (05-2000. )A low dose, short course of Mycophenolate Mofetil (MMF) in combination with Tacrolimus after adult liver transplantation .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Honaker MR, Amiri HS, Alloway RR, Grewal JP, Hardinger K, Kizilisik TA, Bagous T, Trofe J, Vera SR, Gaber AO (05-2000. )Evolving experience of HBV prophylaxis in liver transplant recipients .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Tuteja S, Meier-Kriesch H, Streetman DS, Johnson JA, Gaber AO (05-2000. )The effect of gender on ketoconazole induced changes in tacrolimus pharmacokinetics .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Hathaway DK, Winsett RP, Alloway RR, Cashion AK, Smith MA, Wicks MN, Stratta RJ, Gaber AO (05-2000. )Immunsuppression side effect profile of patients one to twenty years posttransplant .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Egidi MR, Trofe J, Lo A, Stratta RJ, Vera SR, Grewal JP, Amiri MH, Salloum A, Gaber LW, Alloway RR, Gaber AO (05-2000. )Risk factors predisposing liver and kidney transplant patients to the development of post transplant diabetes .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Honaker MR, Lo A, Stratta RJ, Egidi MF, Alloway RR, Amiri MH, Gaber LW, Grewal HP, Hardinger KL, Gaber AO (05-2000. )Impact of HCV status in pancreas transplantation: A case controlled study .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Lo A, Stratta RJ, Alloway RR, Egidi MF, Amiri H, Grewal HP, Kizilisik TA, Gaber AO (05-2000. )Limited benefits of induction with monoclonal antibody to interleukin-2 receptors in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Lo A, Stratta RJ, Egidi MF, Amiri MH, Grewal HP, Alloway RR, Gaber LW, Gaber AO (05-2000. )Outcomes of simultaneous kidney-pancreas transplantation in African-American recipients. A case controlled study .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Egidi MF, Khan N, Hardinger KL, Gaber LW, Sratta RJ, Trofe T, Alloway RR, Gaber AO (05-2000. )Redefining the impact of systemic lupus erythematosus on renal allografts: The need for aggressive surveillance .First Joint Annual Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, Chicago, IL. .

Shokouh-Amiri MH, Egidi MF, Lo A, Grewal HP, Vera SR, Stratta RJ, Khan NA, Trofe J, Alloway RR, Gaber AO (2000. )The Importance of Early Prevention of Renal Dysfunction in Liver Transplant Recipients .18th Annual International Congress of the Transplantation Society,

Aull M, Trofe J, Alloway RR, Hanaway M, First MR, Wagoner L, Beebe T, Woodle ES, Buell JF (02-2001. )PTLD in cardiac transplantation: A report on 274 patients from the Israel Penn International Tumor Transplant Registry .Third International Symposium on Immunodeficiencies, Berlin, Germany. .

Trofe J, Buell J, First MR, Hanaway M, Beebe T, Alloway R, Lo A, Rilo H, Woodle ES (02-2001. )The Israel Penn international tumor transplant registry experience of post transplant lymphoproliferative disorder in kidney transplantation .Third International Symposium on Immunodeficiencies, Berlin, Germany. .

Alexander JW, Metze TJ, Goodman HR, First MR, Cardi MA, Safdhar S, Mendoza NC, Munda R, Fidler JP, Alloway RR, Buell JF, Hanaway MJ, Greenburg NA, Woodle ES (2002. )Simultaneous Corticosteroid Avoidance and Minimization of Calcineurin Inhibitors .American Transplant Congress, Washington, DC. .

Trofe J, Cavallo T, First MR, Roy-Chaudhury P, Peddi R, Weiskittle P, Bryan M, Brown S, Khalili K, Gordon J, Alloway RR, Hanaway MJ, Buell JF, Woodle ES (2002. )Polyomavirus in Kidney and Kidney/Pancreas Transplantation: Minimizing Renal Allograft Injury/Loss by Defined Immunosuppression Reduction and Histologic Monitoring .American Transplant Congress, Washington, DC. .

Peddi VR, Brown S, Hanaway MJ, Buell JF, Alloway RR, Munda R, Woodle ES, First MR (2002. )Efficacy and Cost Analysis of Thymoglobulin (TMG) Induction with Intermittent Dosing Based on CD3+ Lymphocyte Counts in Pancreas Transplant Recipients .American Transplant Congress, Washington, DC. .

Hanaway MJ, Rilo H, Brown S, Peddi VR, Buell JF, Alloway RR, D'Alessio D, Woodle ES (2002. )Hypoglycemic Unawareness: Characterization of Severity in Islet Transplant Candidates .American Transplant Congress, Washington, DC. .

Rilo H, Upshaw L, Hanaway M, Brown S, Fredrickson L, Burke B, D'Alessio D, Alloway RR, Buell J, Woodle ES (2002. )Continuous Glucose Monitoring (CGM): A Potential Objective Means for Determination of Candidacy for Islet Transplantation .American Transplant Congress, Washington, DC. .

Trofe J, Sethuraman G, Buell JH, Hanaway MJ, First MR, Alloway RR, Gross TG, Beebe TM, Woodle ES (2002. )Multivariate Analysis of Risk Factors that Influence Survival in Renal Transplant Recipients with PTLD .American Transplant Congress, Washington, DC. .

Trofe J, Buell J, First MR, Hanaway M, Beebe T, Aull MJ, Gross TG, Hanaway MJ, Alloway RR, Woodle ES (2002. )Renal Allograft Involvement by Post Transplant Lymphoproliferative Disorder: Clinical Implications .American Transplant Congress, Washington, DC. .

Woodle ES, Buell JF, Hanaway MF, Beebe T, Peddi VR, Alloway RR, First MR, Trofe J (2002. )Biologic Behavior of Carcinoid Tumors in Solid Organ Transplant Recipients: The Israel Penn International Transplant Tumor Registry Experience .American Transplant Congress, Washington, DC. .

Aull MJ, Buell JF, Gross T, Trofe J, Alloway RR, Beebe T, Hanaway MJ, First MR, Woodle ES (2002. )Transplantation in Patients with Pre-existing Leukemias .American Transplant Congress, Washington, DC. .

Aull MJ, Buell JF, Gross T, Trofe J, Alloway RR, Beebe T, Hanaway MJ, First MR, Woodle ES (2002. )De Novo Leukemias in Solid Organ Transplant Recipients: A report from the Israel Penn International Transplant Tumor Registry .American Transplant Congress, Washington, DC. .

Buell JF, Hanaway MJ, Trofe J, Alloway RR, Beebe T, Aranda-Michel J, Gross T, First MR, Woodle ES (2002. )Post-transplant Lymphoproliferative Disorder in Liver Transplant Recipients: Comparison Between Children and Adults .American Transplant Congress, Washington, DC. .

Hanaway MJ, Buell JF, James L, Alloway RR, Gross T, Trofe J, Beebe T, First MR, Woodle ES (2002. )De Novo Cancer after Pancreas Transplantation: The IPITTR Experience .American Transplant Congress, Washington, DC. .

Hanaway MJ, Buell JF, Koffron A, Kaufman D, Bruce D, Pelletier R, Henry M, Stratta R, Gaber AO, James L, Alloway RR, First MR, Peddi Vr, Woodle ES (2002. )PTLD in Pancreas Transplantation: A Mutlicenter Analysis .American Transplant Congress, Washington, DC. .

Zavala EY, Rilo HR, Hanaway MJ, Pandolfo A, Alloway RR, First MR, Peddi VR, Brown SF, Buell JF, Matthews JB, Woodle ES (2002. )Economics of Establishing an Islet Isolation Laboratory for Human Islet Transplantation .American Transplant Congress, Washington, DC. .

Boardman R, Alloway RR, Trofe J, Hanaway MJ, Gross TG, First MR, Buell JF, Woodle ES (2002. )Ovarian Cancer in the Transpant Population .International Transplant Nursing Society,

Buell JF, Hanaway MJ, Trofe J, Alloway RR, Beebe T, Aranda-Michel J, Gross T, First MR, Woodle ES (08-2002. )Post-transplant Lymphoproliferative Disorder in Liver Transplant Recipients: Comparison Between Children and Adults .XIX International Congress of Transplant Surgeons, Miami, FL. .

Aull MJ, Buell JF, Gross T, Trofe J, Alloway RR, Beebe T, Hanaway MJ, First MR, Woodle ES (08-2002. )De Novo Leukemias in Solid Organ Transplant Recipients: A report from the Israel Penn International Transplant Tumor Registry .XIX International Congress of Transplant Surgeons, Miami, FL. .

Aull MJ, Buell JF, Gross T, Trofe J, Alloway RR, Beebe T, Hanaway MJ, First MR, Woodle ES (08-2002. )Transplantation in Patients with Pre-existing Leukemias .XIX International Congress of Transplant Surgeons, Miami, FL. .

Hanaway MJ, Buell JF, James L, Alloway RR, Gross T, Trofe J, Beebe T, First MR, Woodle ES (08-2002. )De Novo Cancer after Pancreas Transplantation: The IPITTR Experience .XIX International Congress of Transplant Surgeons, Miami, FL. .

Hanaway MJ, Buell JF, Koffron A, Kaufman D, Bruce D, Pelletier R, Henry M, Stratta R, Gaber AO, James L, Alloway RR, First MR, Peddi Vr, Woodle ES (08-2002. )PTLD in Pancreas Transplantation: A Mutlicenter Analysis .XIX International Congress of Transplant Surgeons, Miami, FL. .

Trofe J, Sethuraman G, Buell JH, Hanaway MJ, Aull MJ, Alloway RR, Wagoner, Beebe TM, Gross TG, First MR, Woodle ES (08-2002. )Multivariate Analysis of Risk Factors that Influence Survival in Cardiac Transplant Recipients with PTLD .XIX International Congress of Transplant Surgeons, Miami, FL. .

Trofe J, Buell JF, First MR, Beebe TM, Aull MJ, Gross TG, Hanaway MJ, Alloway RR, Woodle ES (08-2002. )Renal Allograft Involvement by Post Transplant Lymphoproliferative Disorder: Clinical Implications .XIX International Congress of Transplant Surgeons, Miami, FL. .

Trofe J, Sethuraman G, Buell JH, Hanaway MJ, First MR, Alloway RR, Gross TG, Beebe TM, Woodle ES (08-2002. )Multivariate Analysis of Risk Factors that Influence Survival in Renal Transplant Recipients with PTLD .XIX International Congress of Transplant Surgeons, Miami, FL. .

Trofe J, Cavallo T, First MR, Roy-Chaudhury P, Peddi R, Weiskittle P, Bryan M, Brown S, Khalili K, Gordon J, Alloway RR, Hanaway MJ, Buell JF, Woodle ES (08-2002. )Polyomavirus Interstitial Nephritis in Kidney Pancreas Transplantation: Minimizing Renal Allograft Loss by Histologic Monitoring Defined Immunosuppression Reduction .XIX International Congress of Transplant Surgeons, Miami, FL. .

Trofe J, Buell JF, First MR, Beebe TM, Hanaway MJ, Alloway RR, Woodle ES, Gross TG (08-2002. )Recurrence of Lymphoma Following Organ Transplantation .XIX International Congress of Transplant Surgeons, Miami, FL. .

Zavala EY, Rilo HR, Hanaway MJ, Pandolfo A, Alloway RR, First MR, Peddi VR, Brown SF, Buell JF, Matthews JB, Woodle ES (08-2002. )Financial Considerations of Establishing an Islet Isolation Laboratory for Human Islet Transplantation .XIX International Congress of Transplant Surgeons, Miami, FL. .

Zavala EY, Rilo HR, Hanaway MJ, Brown SF, Peddi VR, First MR, Martin JE, Alloway RR, Buell JF, Matthews JB, Woodle ES (08-2002. )The Clinical Economics of Human Islet Transplantation .XIX International Congress of Transplant Surgeons, Miami, FL. .

Gross TG, Buell JF, Hanaway MJ, Beebe Tm, Trofe J, Alloway RR, First MR, Woodle ES (08-2002. )Wilm's Tumor and Organ Transplantation .XIX International Congress of Transplant Surgeons, Miami, FL. .

Alloway RR (05-2004. )Conversion of stable kidney transplant recipients from a twice-daily Prograf based regimen to a once daily modified release tacrolimus based regimen .American Transplant Congress, Boston, MA. .

Alloway RR, Trofe J, Boardman RE, Rogers CC, Kidd M, Buell JF, hanaway MJ, Munda R, Alexander JW, Thomas MJ, Roy-Chaudhury P, Cardi MA, Austin J, Goel S, Safdar S, Huang S, Woodle ES (05-2004. )A prospective pilot study of early corticosteroid elimination under modern immunosuppression in patients at high immunologic risk: One-year results .American Transplant Congress, Boston, MA. .

Buell JF, Beebe TM, Papaconstantinou HT, Gross TG, Hanaway MJ, Trofe J, Alloway RR, Woodle ES (05-2004. )Squamous cell carcinoma of the perineum and rectum in transplant recipients .American Transplant Congress, Boston, MA. .

Buell JF, Beebe TM, Gross TG, Hanaway MJ, First MR, Muthiah C, Trofe J, Alloway RR, Woodle ES (05-2004. )Malignancy transmission from donors with melanoma .American Transplant Congress, Boston, MA. .

Buell JF, Beebe TM, Muthiah C, Gross TG, First MR, Hanaway MJ, Trofe J, Alloway RR, Woodle ES (05-2004. )Aggressive skin cancers in transplant recipients .American Transplant Congress, Boston, MA. .

Hanaway MJ, Buell JF, Gross TG, Trofe J, Beebe TM, Alloway RR, Rudich SM, Woodle ES (05-2004. )Effect of sites of presentation of PTLD markedly influences survival after solid organ transplantation .American Transplant Congress, Boston, MA. .

Rogers CC, Beebe TM, Hanaway MJ, Thomas MJ, Gross TG, Rudich SM, First MR, Alloway RR, Trofe J, Woodle ES (05-2004. )Immunomodulation impacts survival of donor transmitted malignancies .American Transplant Congress, Boston, MA. .

Stratta R, Alloway R, Lo A, Hodge E (05-2004. )A multicenter analysis on the significance of HLA matching on outcomes following kidney-pancreas transplantation .American Transplant Congress, Boston, MA. .

Woodle ES, Susskind B, Alloway R, Hanaway M, Thomas M, Alexander J, Merchen T, Gupta M, Succop P, Roy-Chaudhury P, Cardi M, Boardman R, Rogers C (05-2004. )Histocompatability testing predicts acute renal allograft rejection risk in early corticosteroid cessation (ECS) regimens .American Transplant Congress, Boston, MA. .

Rudich S, Hanaway M, Beebe T, Alloway R, Gross T, Woodle E, Buell J (06-2004. )De novo malignancies in liver transplant recipients: A single center study .International Liver Transplantation Society 10th Annual Congress, Kyoto, Japan. .

Beebe T, Buell J, Papaconstantinou H, Skalow B, Gross T, Hanaway M, Alloway R, Trofe J, Woodle E (09-2004. )Differences in survival patterns between transplant recipients and general population patients developing de novo colorectal cancer .XX International Congress of the Transplantation Society, Vienna, Austria. .

Beebe T, Buell J, Gross T, Hanaway M, Trofe J, Alloway R, Woodle E (09-2004. )Skin malignancy in transplant recipients .XX International Congress of the Transplantation Society, Vienna, Austria. .

Boardman R, Trofe T, Alloway R, Rogers C, Roy-Chaudhury P, Cardi M, Safdar S, Buell J, Hanaway M, Thomas M, Alexander J, Munda R, Woodle E (09-2004. )Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis .XX International Congress of the Transplantation Society, Vienna, Austria. .

Boardman R, Alloway R, Rogers C, Clippard M, Gupta M, Merchen T, Metze T, Susskind B, Trofe J, Peddi V, Woodle E (09-2004. )African American renal transplant recipients: Experience with early corticosteroid cessation under modern immunosuppression .XX International Congress of the Transplantation Society, Vienna, Austria. .

Buell J, Beebe T, Gross T, Hanaway M, Alloway R, Trofe J, Woodle E (09-2004. )Donor assessment: Is a policy change warranted? .XX International Congress of the Transplantation Society, Vienna, Austria. .

Gross T, Buell J, Beebe T, Hanaway M, Trofe J, Alloway R, Woodle E (09-2004. )Can donor kidneys with small renal cell cancers be safely transplanted? .XX International Congress of the Transplantation Society, Vienna, Austria. .

Hanaway M, Buell J, Roy-Chaudhury P, Thomas M, Rudich S, Boardman R, Rogers C, Alloway R, Woodle E (09-2004. )Corticosteroid elimination in renal transplantation: Experience in high immunologic risk recipients .XX International Congress of the Transplantation Society, Vienna, Austria. .

Merchen T, Buell J, Beebe T, Gross T, Hanaway M, Trofe J, Alloway R, Woodle E (09-2004. )Renal cell cancer donor tumor transmission .XX International Congress of the Transplantation Society, Vienna, Austria. .

Rogers C, Cardi M, Alloway R, Boardman R, Trofe J, Hanaway M, Alloway R, Woodle E (09-2004. )Global cardiovascular risk under early steroid cessation decreases progressively in the first year post-transplant .XX International Congress of the Transplantation Society, Vienna, Austria. .

Rogers C, Alloway R, Alexander J, Buell J, Boardman R, Cardi M, Roy-Chaudhury P, First M, Hanaway M, Succop P, Metze T, Munda R, Woodle E (09-2004. )Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression .XX International Congress of the Transplantation Society, Vienna, Austria. .

Rudich S, Neff G, Gupta M, Beebe T, Gross T, Hanaway M, Alloway R, Trofe J, Woodle E, Buell J (09-2004. )De noveo anorectal cancers in renal transplant recipients .XX International Congress of the Transplantation Society, Vienna, Austria. .

Trofe J, Roy-Chaudhury P, Gordon J, Wadih G, Alloway R, Khalili K, Woodle E (09-2004. )Viral load monitoring in patients with polyomavirus nephropathy who have been treated for rejection episodes .XX International Congress of the Transplantation Society, Vienna, Austria. .

Trofe J, Gordon J, Roy-Chaudhury P, Wadih G, Alloway R, Succop P, Jain A, Khalili K, Woodle E (09-2004. )Outcomes of patients with polyomavirus nephropathy and rejection .XX International Congress of the Transplantation Society, Vienna, Austria. .

Woodle ES, Beebe TM, Gross TG, Trofe J, Muthiah C, Hanaway M, First MR, Alloway RR, Buell JF (09-2004. )Re-transplantation after post transplant lymphoproliferative disorder .XX International Congress of the Transplantation Society, Vienna, Austria. .

Vinks A, Cox S, Rogers C, Alexander J, Woodle E, Alloway R (04-2005. )Pharmacokinetics of Mycophenolic Acid in patients who have undergone gastric bypass surgery .International Congress on TDM and Clinical Toxicology, Louisville, KY. .

Rike A, Mogilishetty G, Alloway R, Succop P, Roy-Chaudhury P, Ueda K, Cardi M, Thomas M, Woodle E (04-2005. )Predictors of cardiovascular disease in renal transplant recipients .2005 Spring Practice and Research Forum of the American College of Clinical Pharmacy, Myrtle Beach, South Carolina. .

Alonzo M, Alloway R, Thambi-Pillai T, Tevar A, Hanaway M, Buell J, Thomas M, Koralnik I (05-2005. )An analysis of Hepatitis C Virus re-infection in liver transplants performed using criteria donor allografts .American Transplant Congress, Seattle, WA. .

Chen Y, Trofe J, Gordon J, Roy-Chaudhury P, Woodle E, Alloway R, Khalili K, Koralnik I (05-2005. )Cytotoxic lymphocytes control BK Virus replication in renal transplant recipients with polyomavirus nephropathy .American Transplant Congress, Seattle, WA. .

Kaiser TE, Roy-Chaudhury P, Susskind B, Alloway R, Trofe J, Braily P, Rike A, Arend L, Cardi M, Austin J, Woodle E (05-2005. )Donor specific antibody detection by solid phase assay is a strong predictor of C4d postivitiy in renal allograft biopsies performed to evaluate renal dysfunction .American Transplant Congress, Seattle, WA. .

Kaiser TE, Alloway R, Mogilishetty G, Roy-Chaudhury P, Rike A, Young S, Woodle E, Hanaway M (05-2005. )Early corticosteroid elimination with extended thymoglobulin therapy provides lower acute rejection compared to steroid treated controls in simultaneous kidney pancreas transplantation .American Transplant Congress, Seattle, WA. .

Mogilishetty G, Rike A, Alloway R, Woodle E, Succop P, Kaiser T, Cardi M, Thomas M, Buell J, Roy-Chuadhury P (05-2005. )Predictors of cardiovascular disease risk in renal transplant recipients .American Transplant Congress, Seattle, WA. .

Rike A, Mogilishetty G, Alloway R, Succop P, Kaiser T, Roy-Chaudhury P, Hanaway M, Woodle E, Munda R (05-2005. )Early corticosteroid cessation minimizes new onset metabolic syndrome following renal transplantation .American Transplant Congress, Seattle, WA. .

Tevar A, Kaiser T, Rike A, Thambi-Pillai T, Alloway R, Woodle E, Hanaway M, Schneider C, Buell J (05-2005. )Comparison of allograft renal function between right-sided laparspcopic donor nephrectomy and multiple vessel left-sided laparoscopic donor nephrectomy .American Transplant Congress, Seattle, WA. .

Ueda KR, Jain A, Roy-Chaudhury P, Alloway R, Succop P, Kaiser T, Mogilishetty G, Cardi M, Safdar S, Woodle E (05-2005. )Anemia in kidney transplant recipients: A multivariate analysis .American Transplant Congress, Seattle, WA. .

Woodle E, Alloway R, Roy-Chaudhury P, Alexander W, Hanaway M, Munda R, Tevar A, Rike A (05-2005. )A multivariate analysis of early and late acute rejection risk in 318 renal transplants following early corticosteroid withdrawal .American Transplant Congress, Seattle, WA. .

Stratta R, Alloway R, Lo A, Hodge E, Rogers J (01-2006. )A prospective randomized multicenter trial of Daclizumab induction in simultaneous kidney-pancreas transplantation: Risk factors for rejection and adverse long-term outcomes at 3 years .American Society of Transplant Surgeons Winter Symposium, Arizona. .

Stratta R, Alloway R, Lo A, Hodge E, Rogers J (01-2006. )A newly identified risk factor for adverse long-term outcomes following simultaneous kidney-pancreas transplantation .American Society of Transplant Surgeons Winter Symposium, Arizona. .

Alloway R, Vanhaecke J, Yonan N, White M, Haddad H, Rabago G, Tymchak W, Diaz Molina B, Grimm M, Eiskjaer H, Palomo J, Roig E, Trochu J, Bara C, Pulpon L, Korfer R, Undre N (12-2005. )Conversion of stable heart transplant recipients from twice daily prograf to once daily modified release tacrolimus .European Society of Organ Transplant, Geneva, Switzerland. .

Rike A, Mogilishetty G, Alloway R, Succop P, Roy-Chaudhury P, Kaiser T, Ueda K, Woodle E (10-2005. )Cardiovascular risk and events in renal transplant recipients receiving early corticosteroid withdrawal versus chronic corticosteroids .American College of Clinical Pharmacy, San Francisco, CA. .

Alonzo M, Kaiser T, Martin J, Rike A, Cavanaugh T, Alloway R, Mogilishetty G, Zacharias V, Kemmer N, Neff G (07-2006. )Analysis of liver transplant recipients with chronic renal disease using monotherapy sirolimus vs combination tacrolimus with sirolimus .World Transplant Congress, Boston, MA. .

Balducci A, Rike A, Alloway R, Cardi M, Clippard M, Weimart N, Thomas M, Munda R, Tevar A, Woodle E (07-2006. )T cell depleting antibody induction and delayed calcineurin inhibitor introduction in early corticosteroid withdrawal regimens: An analysis .World Transplant Congress, Boston, MA. .

Balducci A, Rike A, Alloway R, Huang S, Clippard M, Walker J, Buell J, Tevar A, Woodle E (07-2006. )Early corticosteroid withdrawal in deceased donor kidney transplants with delayed graft function: Two year results .World Transplant Congress, Boston, MA. .

Balducci A, Rike A, Alloway R, Cardi M, Clippard M, Weimart N, Safdar S, Thomas M, Tevar A, Woodle E (07-2006. )Effects of delayed graft function and delayed creatinine clearance in early corticosteroid withdrawal regimens .World Transplant Congress, Boston, MA. .

Buell J, Gross T, Muthiah C, Thomas M, Neff G, Alloway R, Woodle E (07-2006. )Malignancies in pediatric transplant recipients .World Transplant Congress, Boston, MA. .

Kaiser T, Susskind B, Alloway R, Roy-Chaudhury P, Mogilishetty G, Tevar A, Rike A, Jain A, Munda R, Woodle E (07-2006. )Early corticosteroid cessation in living donor renal transplant recipients with positive flow cytometric crossmatches: 2 year experience .World Transplant Congress, Boston, MA. .

Kaiser T, Mogilishetty G, Roy-Chaudhury P, Weimert N, Zacharias V, Kemmer N, Alloway R, Tevar A, Buell J, Neff G (07-2006. )Liver failure etiology: Can it be used to predict progression of renal dysfunction? .World Transplant Congress, Boston, MA. .

Rike A, Alloway R, Mogilishetty G, Weimert N, Succop P, Cardi M, Young S, Thomas M, Woodle E (07-2006. )Evaluation of new predictors of cardiovascular risk and cardiovascular events following renal transplantation .World Transplant Congress, Boston, MA. .

Rike A, Mogilishetty G, Alloway R, Cardi M, Roy-Chaudhury P, Succop P, Buell J, Woodle E (07-2006. )Metabolic syndrome in renal transplantation: Comparison of early corticosteroid withdrawal vs chronic corticosteroid therapy .World Transplant Congress, Boston, MA. .

Woodle E, First M, Gaber A, Alloway RR, Pirsch J, Shihab F, Holman J, Reisfeld R, Astellas Steroid Withdrawal Group (07-2006. )Are living donor kidney transplant recipients better candidates for early corticosteroid withdrawal than deceased donor recipients? .World Transplant Congress, Boston, MA. .

Alloway R, Mogilishetty G, Cole L, Vasilic D, Barker J, Skeens E, Holland P, Roy-Chaudhury P (05-2007. )Ocular surface transplant recipients experience fewer immunosuppression complications than renal transplant recipients: Implications for facial and composite tissue transplantation .American Transplant Congress, San Francisco, CA. .

Adele H, Rike A, Cardi M, Alloway R, Weimert N, Clippard M, Woodle E (05-2007. )Outcomes of prospective Mycophenolic acid abbreviated area under the curve monitoring and Mycophenolate Mofetil dosing in renal transplantation .American Transplant Congress, San Francisco, CA. .

Kim D, Everly J, Tevar A, Rudich S, Gross T, First M, Alloway R, Woodle E (09-2007. )Comparison of post transplant lymphoproliferative disease between liver and kidney transplant population from Israel Penn International Transplant Tumor Registry .Transplant Summit 2007, Chicago, IL. .

Alloway R, Germain M, Gaber A, Bodziak K, Mulgaonkar S, Gohh R, Kaplan E, Beckery M, Gordon R (06-2008. )A phase II, open label, multi-center prospective, conversion study in stable kidney transplant patients to compare pharacokinetics of LCP-Tacro tablets once-a-day to Prograf capsules twice-a-day .American Transplant Congress, Toronto, Ontario. .

Everly J, Miao Y, Gross T, First M, Tevar A, Alloway R, Webster A, Woodle E (06-2008. )Influence of immunosuppression on renal cell carcinoma: Comparison of outcomes with renal cell carcinoma in transplant recipients and the general population .American Transplant Congress, Toronto, Ontario. .

Everly M, Everly J, Brailey P, Susskind B, Arend L, Govil A, Young S, Alloway R, Woodle E (06-2008. )Early reduction in immunodominant de novo donor specific anti-HLA antibody levels predicts long term renal allograft survival .American Transplant Congress, Toronto, Ontario. .

Everly M, Everly J, Brailey P, Susskind B, Arend L, Govil A, Young S, Alloway R, Roy-Chaudhury P, Cardi M, Safdar S, Tevar A, Woodle E (06-2008. )Presence of a donor specific humoral response in acute rejection significantly reduces long-term renal allograft survival .American Transplant Congress, Toronto, Ontario. .

Lee R, Rike A, Alloway R, Everly J, Mogilishetty G, Cole L, Cardi M, Safdar S, Woodle E (06-2008. )Statin therapy in kidney transplant recipients: Effects on cardiovascular events, death and acute rejection .American Transplant Congress, Toronto, Ontario. .

Meyer I, Alloway R, Meyer M, Woodle E, Jane A, Bennett M, Devarajan P, Roy-Chaudhury P, Thakar C (06-2008. )Change in urinary neutrophil gelatinase-associated lipcalin (NGAL) as a predictor of allograft function .American Transplant Congress, Toronto, Ontario. .

Mogilishetty G, Hair D, Alloway R, Everly M, Cole L, Meyer M, Govil A, Roy-Chaudhury P, Holland E, Woodle E (06-2008. )Comparison of immunosuppression related toxicities and complications in ocular surface transplant and renal transplant and renal transplant recipients: Implications for composite tissue transplantation .American Transplant Congress, Toronto, Ontario. .

Rike A, Everly J, Alloway R, Cardi M, Lee R, Mogilishetty G, Meyer M, Munda R, Woodle E (06-2008. )Correlation of cardiovascular events in kidney transplant recipients with traditional versus non-traditional risk factors .American Transplant Congress, Toronto, Ontario. .

Lee R, Rike A, Alloway R, Everly J, Govil A, Durbin J, Woodle E (08-2008. )Statin therapy and corticosteroid therapy in kidney transplantation: Effects on cardiovascular event and death rates .XXII International Congress of The Transplantation Society, Sydney, Australia. .

Rike A, Everly J, Alloway R, Cardi M, Mogilishetty G, Safdar S, Durbin J, Woodle E (08-2008. )Framingham risk assessment by actual cardiovascular event data in renal transplant recipients .XXII International Congress of The Transplantation Society, Sydney, Australia. .

Rike A, Everly J, Alloway R, Mogilishetty G, Cardi M, Clippard M, Munda R, Woodle E (08-2008. )Traditional vs nontraditional risk factors for cardiovascular events in kidney transplant recipients .XXII International Congress of The Transplantation Society, Sydney, Australia. .

Alloway R, Mulgaonkar S, Bowers V, Ueda Stevenson K, Cohen D, Katz E, Kosar H, Gordon R, Jexner Hamberg K, Chodoff L (06-2009. )A phase 2b, open-label, multi-center, prospective, randomized study to compare the pharmacokinetics and safety of LCP-Tacro tablets once-a-day to Prograf capsules twice-a-day in de novo kidney transplant patients .American Transplant Congress, Boston, MA. .

Govil A, Everly M, Arend L, Everly J, Brailey P, Mogilishetty G, Alloway R, Woodle E, Roy-Chaudhury P (06-2009. )Glomerular C4D deposition and de novo donor specific antibodies are associated with poor prognosis in transplant glomerulopathy .American Transplant Congress, Boston, MA. .

Hibbs J, Everly J, Alloway R, Rike A, Mogilishetty G, Govil A, Tevar A, Huang S, Woodle E (06-2009. )Early corticosteroid withdrawal is not associated with progressive deterioration in renal allograft survival or function .American Transplant Congress, Boston, MA. .

Hibbs J, Everly J, Rike A, Alloway R, Govil A, Mogilishetty G, Tevar A, Safdar S, Woodle E (06-2009. )Early corticosteroid withdrawal is not associated with an increased acute rejection risk: A five year experience in 800 patients .American Transplant Congress, Boston, MA. .

Walsh R, Everly J, Alloway R, Rike A, Mogilishetty G, Govil A, Roy-Chaudhury P, Cardi M, Woodle E (06-2009. )Early corticosteroid withdrawal in patients with focal segmental glomerulosclerosis: 10-year results .American Transplant Congress, Boston, MA. .

Zand M, Alloway R, Brailey P, Girnita A, Walsh R, Woodle R (05-2010. )Changes in protective antibody levels for influenza A and cytomegalovirus after treatment of antibody mediated rejection and bortezomib, rituximab, and plasmapheresis .American Transplant Congress, San Diego, CA. .

Walsh R, Shields A, Mogilishetty G, Govil A, Roy-Chaudhury P, Young S, Wall G, Safdar A, Huang S, Cardi M, Alloway R, Woodle E (08-2010. )Prospective analysis of adverse event profile of proteasome inhibitor-based antihumoral therapy for renal transplant candidates and recipients .XXIII International Congress of The Transplantation Society, Vancouver, Canada. .

Walsh R, Girnita A, Wall G, Shields A, Brailey P, Mogilishetty G, Govil A, Cardi M, Alloway R, Woodle E (08-2010. )Single antigen bead analysis of a highly sensitized deceased donor kidney transplant waitlist .XXIII International Congress of The Transplantation Society, Vancouver, Canada. .

Walsh R, Girnita A, Walle G, Brailey P, Mogilishetty G, Govil A, Huang S, Safdar S, Alloway R, Woodle E (08-2010. )Evaluation of unacceptable antibody threshold in sensitized deceased donor kidney transplant waitlist .XXIII International Congress of The Transplantation Society, Vancouver, Canada. .

Schmidt N, Woodle E, Alloway R, Mogilishetty G, Tevar A, Young S, Cole L, Hanseman D, Shields A (03-2011. )Early corticosteroid withdrawal reduces risk for actual cardiovascular events in renal transplant recipients: A multivariate analysis .AST-CST Distinguished Fellows Symposium, Mont-Tremblant, Quebec. .

Sadaka B, Alloway R, Girnita A, Brailey P, Mogilishetty G, Woodle E (05-2011. )Multivariate analysis of risk factors that influence graft survival following proteasome inhibitor (PI) therapy for antibody-mediated rejection .Trainees Research Grand Rounds at University of Cincinnati, Cincinnati, OH. .

Woodle E, Girnita A, Brailey P, Sadaka B, Rike-Shields A, Alloway R, Wall G (09-2011. )Desensitization results are influences by the nature of the HLA Ab being treated .Congress of the European Society for Organ Transplantation, Glasgow, Scotland. .

Schmidt N, Woodle E, Alloway R, Mogilishetty G, Tevar A, Young S, Cole L, Hanseman D, Shields A (10-2011. )Early corticosteroid withdrawal reduces risk for actual cardiovascular events in renal transplant recipients: A multivariate analysis .ACCP Annual Meeting, Pittsburgh, PA. .

Schmidt N, Shields A, Alloway R, Mogilishetty G, Cardi M, Munda R, Tevar A, Burns J, Kremer J, Cole L, Young S, Hanseman D, Safdar S, Woodle E (10-2011. )10-year experience with early corticosteroid elimination in kidney transplantation: Analysis of patient and graft survival .ACCP Annual Meeting, Pittsburgh, PA. .

Paper Presentations

Alloway, R (08-1992. )Low Dose OKT3 Induction Therapy of Cadaveric Transplant Recipients .

Alloway R (08-1995. )Conversion from Cyclosporine to FK-506 in Kidney, Kidney/Pancreas and Pancreas Alone Transplant Recipients. A Single Center Experience .Minneapolis, MN.

Alloway R (05-1997. )Effect of Gut Metabolism on Tacrolimus Bioavailability in Renal Transplant Recipients .Chicago, IL.

Alloway R (05-1997. )An Open-Labeled Single Center Bioequivalence Comparison of Sandimmune and Noral versus Sang-35 Cyclosporine .Chicago, IL.

Alloway R (05-1998. )Bioequivalence of Sang-35 and Neoral for Cyclosporine Metabolites in Stable Renal Transplant Recipients .Chicago, IL.

Alloway R (09-2004. )Conversion of stable kidney transplant recipients from a twice daily prograf based regimen to a once daily modified release tacrolimus based regimen .Vienna, Austria.

Alloway R (10-2004. )Conversion of stable kidney transplant recipients from a twice daily prograf based regimen to a once daily modified release tacrolimus based regimen .San Diego, CA.

Alloway R (05-2005. )A one year follow up of the stable liver transplant recipients converted from twice daily Prograf to once daily modified release Tacrolimus .Seattle, WA.

Alloway R (07-2006. )A two year follow-up study of stable kidney transplant recipients converted from twice daily Prograf to once daily modified release Tracrolimus .Boston, MA.

Alloway R, Vanhaecke J, Yonan N, White M, Haddad H, Rabago G, Tymchak W, Diaz Molina B, Grimm M, Eiskjaer H, Palomo J, Roig E, Trochu J, Bara C, Pulpon L, Korfer R, Undre N (07-2006. )Conversion of stable heart transplant recipients from twice daily prograf to once daily modified release tacrolimus .Boston, MA.

Alloway R, Woodle E, Gaber A, Pirsch J, Shihab F, Van Veldhuisen P, Gao J, First M, Holman J, Fitzsimmons W, Reisfeld R, Astellas Steroid Withdrawal Study Group (07-2006. )Multivariate analysis of risk factors for acute rejection with early (7 day) corticosteroid withdrawal: Results from a randomized, double-blind, placebo-controlled trial .Boston, MA.

Alloway R, Skeens H, Cole L, Mogilishetty G, Holland E, Vasilic D, Barker J, Roy-Chaudhury P, Woodle E (05-2009. )Ocular Surface Transplant Recipients Experience Minimal Immunsuppression Complications: Implications for Composite Tissue Transplants .San Francisco, CA.

Alloway R (08-2008. )A three year follow-up study of stable kidney transplant recipients converted twice daily Prograf to once daily extended release Tacrolimus .Sydney, Australia.

Alloway R (08-2008. )A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with Tacrolimus and Thymoglobulin in early corticosteroid withdrawal .Sydney, Australia.

Alloway R, Sadaka B, Woodle E (05-2011. )Evaluation of surrogate endpoints and stratification factors for antibody mediated for antibody mediated rejection registration trials .Philadelphia, PA.

Rogers C, Alexander J, Alloway R, Boardman R, Trofe J, Gupta M, Merchen T, Buell J, Hanaway M, Cardi M, Roy-Chaudhury P, Woodle E (09-2004. )Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy: 2 year follow up in 109 patients .Vienna, Austria.

Kaiser TE, Susskind BM, Alloway RR, Roy-Chaudhury P, Trofe J, Braily P, Ueda K, Cardi M, Thomas M, Goel S, Woodle E (05-2005. )Early corticosteroid cessation in living donor renal transplant recipients with positive flow cytometric crossmatches: 2 year experience .Seattle, WA.

Rike A, Mogilishetty G, Alloway R, Succop P, Roy-Chaudhury P, Ueda K, Cardi M, Thomas M, Woodle E (05-2005. )Global cardiovascular risk events in renal transplant recipients receiving early corticosteroid withdrawal versus chronic corticosteroids .Seattle, WA.

Rike A, Alloway R, Roy-Chaudhury P, El-Khatib M, Mogilishetty G, Hanaway M, Munda R, Buell J, Woodle E (05-2005. )Long-term effects of acute rejection episodes following early corticosteroid cessation in renal transplantation .Seattle, WA.

Rogers C, Alloway R, Alexander J, Buell J, Boardman R, Cardi M, Goel S, Goodman H, Huang S, Safdar S, Trofe J, Woodle E, Vinka A (05-2005. )A pilot study to determine the pharmacokinetics of various immunosuppressants in transplant recipients who have undergone gastric bypass surgery .Seattle, WA.

Alonzo M, Alloway R, Thambi-Pillai T, Tevar A, Hanaway M, Buell J, Thomas M, Neff G, Weber F, Rudich S (07-2005. )An analysis of Hepatitis C Virus re-infection in liver transplants performed using criteria donor allografts .Los Angeles, CA.

Walker J, Boardman R, Alloway R< Arend L, Mogilishetty G, Roy-Chaudhury P, Cole E, Thomas M, Cardi M, Woodle E (07-2006. )Early corticosteroid withdrawal in patients with focal segmental glomerulosclerosis: 3-year results .Boston, MA.

Walker J, Trofe J, Alloway R, Weimer N, Succop P, Buell J, Tevar A, Roy-Chaudhury P, Cardi M, Woodle E (07-2006. )Polyomavirus nephropathy: Multivariate analysis of risk factors with early corticosteroid cessation .Boston, MA.

Walker J, Alloway R, Weimer N, Cardi M, Balducci A, Rike A, Roy-Chaudhury P, Mogilishetty G, Buell J, Munda R, First M, Thomas M, Woodle E (07-2006. )A steroid-free, short-term calcineurin inhibitor, long-term, MMF monotherapy regimen for HLA identical live donor kidney transplantation: A prospective trial .Boston, MA.

Weimert N, Kaiser T, Arend L, Jain A, Mogilishetty G, Revello P, Alloway R, Cardi M, Susskind B, Woodle E (07-2006. )Pattern of C4d deposition in patients with and without donor specific antibodies .Boston, MA.

Everly M, Everly J, Brailey P, Susskind B, Alloway R, Woodle E (06-2008. )De novo donor specific antibodies during acute rejection: Effects on induction efficacy .Toronto, Ontario.

Lee R, Rike A, Alloway R, Everly J, Govil A, Young S, Cardi M, Woodle E (06-2008. )Thymoglobulin dosing intensity and density: Effects on induction efficacy .Toronto, Ontario.

Everly M, Everly J, Brailey P, Susskind B, Arend L, Govil A, Young S, Alloway R, Roy-Chaudhury P, Tevar A, Woodle E (08-2008. )The presence of an antibody component in acute cellular rejection decreases renal allograft survival .Sydney, Australia.

Everly M, Everly J, Brailey P, Susskind B, Alloway R, Woodle E (08-2008. )Humoral responses to donor HLA antigens during acute rejection are independent predictors of renal allograft loss .Sydney, Australia.

Everly M, Everly J, Brailey P, Susskind B, Arend L, Govil A, Roy-Chaudhury P, Mogilishetty G, Woodle E (08-2008. )Proteasome inhibition effectively treats acute cellular rejection, antibody mediated rejection and provides long-term reduction of donor specific antibodies .Sydney, Australia.

Everly M, Arend L, Govil A, Susskind B, Al-Ghawi H, Everly J, Mogilishetty G, Alloway R, Woodle E, Roy-Chaudhury (08-2008. )The presence of de novo donor specific antibody predicts poor allograft survival in patient with transplant glomerulopathy .Sydney, Australia.

Everly M, Everly J, Brailey P, Susskind B, Arend L, Govil A, Young S, Alloway R, Tevar A, Woodle E (08-2008. )Effective reduction of immunodominant de novo donor specific anti-HLA antibody levels decreases renal allograft loss .Sydney, Australia.

Lee R, Rike A, Alloway R, Everly J, Roy-Chaudhury P, Govil A, Clippard M, Woodle E (08-2008. )Thymoglobulin dosing intensity and density: Effects on induction efficacy in early corticosteroid withdrawal regimens .Sydney, Australia.

Lee R, Rike A, Alloway R, Everly J, Roy-Chaudhury P, Cole L, Woodle E (08-2008. )Reversal of metabolic syndrome post-kidney transplantation in chronic corticosteroid versus early corticosteroid withdrawal regimens .Sydney, Australia.

Lee R, Rike A, Alloway R, Everly J, Mogilishetty G, Young S, Woodle E (08-2008. )New onset metabolic syndrome after renal transplantation: Effects of maintenance steroid therapy and diabetes .Sydney, Australia.

Hibbs J, Everly J, Alloway R, Rike A, Mogilishetty G, Govil A, Cardi M, Munda R, Woodle E, Rike A (05-2009. )Early corticosteroid withdrawal reduces cardiovascular events in renal transplant recipients .Boston, MA.

Hibbs J, Everly J, Alloway R, Rike A, Mogilishetty G, Govil A, Cardi M, Munda R, Woodle E, Rike A (05-2009. )Maintenance corticosteroid therapy is associated with an increased incidence of cardiovascular events in renal transplant recipients .Boston, MA.

Hibbs J, Everly J, Alloway R, Mogilishetty G, Govil A, Tevar A, Huang S, Woodle E, Rike A (06-2009. )Early corticosteroid withdrawal is not associated with progressive deterioration in renal allograft survival or function .Boston, MA.

Walsh R, Everly J, Everly M, Brailey P, Alloway R, Rike A, Arend L, Mogilishetty G, Govil A, Tevar A, Woodle E (06-2009. )Bortezomib treatment for refractory acute humoral rejection: Intermediate results .Boston, MA.

Walsh R, Everly J, Everly M, Brailey P, Alloway R, Rike A, Arend L, Mogilishetty G, Govil A, Tevar A, Woodle E (06-2009. )Bortezomib treatment for antibody-mediated rejection: Analysis of factors that influence therapeutic response .Boston, MA.

Walsh R, Everly J, Rike A, Brailey P, Alloway R, Arend L, Mogilishetty G, Govil A, Tevar A, Woodle E (09-2009. )Bortezomib treatment for antibody-mediated rejection: differential response in early versus late post-transplant AMR .Minneapolis, MN.

Walsh R, Everly J, Rike A, Brailey P, Alloway R, Arend L, Mogilishetty G, Govil A, Tevar A, Woodle E (10-2009. )Bortezomib-based treatment of antibody mediated rejection (AMR): comparison of efficacy in early versus late-post-transplant AMR .San Diego, CA.

Walsh R, Shields A, Wall G, Brailey P, Girnita A, Cardi M, Govil A, Mogilishetty G, Alloway R, Woodle E (05-2010. )A prospective, staged trial of proteasome inhibitor-based therapy for reduction of HLA sensitization in kidney transplant candidates .San Diego, CA.

Walsh R, Brailey P, Girnita A, Wall G, Alloway R, Cardi M, Govil A, Tevar A, Safdar S, Arend L, Woodle E (05-2010. )Proteasome inhibitor-based antihumoral therapy: differential response in early versus late antibody mediated rejection .San Diego, CA.

Walsh R, Shields A, Safdar S, Huang S, Cardi M, Govil A, Mogilishetty G, Roy-Chaudhury P, Young S, Alloway R, Woodle E (05-2010. )Toxicity profile of proteasome inhibitor-based antihumoral therapy in renal transplant candidates and recipients .San Diego, CA.

Walsh R, Shields A, Safdar S, Huang S, Cardi M, Govil A, Mogilishetty G, Roy-Chaudhury P, Cole L, Alloway R, Woodle E (05-2010. )Prospective analysis of peripheral neuropathy with bortezomib-based therapy for antibody mediated rejection and desensitization .San Diego, CA.

Woodle E, Light J, Rubin M, Thielke J, Morrow W, Mahle W, Franklin C, Gabardi S, Gill J, Roberti I, Shapiro R, Wall G, Walsh R, Zand M, Alloway R (05-2010. )Proteasome inhibitor therapy for antibody mediated rejection: Initial report from a multicenter collaborative .San Diego, CA.

Woodle E, Girnita, Brailey P, Zand M, Walsh R, Alloway R (05-2010. )Plasma cell targeted therapy in antibody mediated rejection: pretransplant HLS antibody screening predicts responses .San Diego, CA.

Walsh R, Shields A, Wall G, Girnita A, Brailey P, Cardi M, Govil A, Mogilishetty G, Alloway R, Woodle E (08-2010. )Prospective, staged trial of a proteasome inhibitor-based desensitization protocol for kidney transplant candidates .Vancouver, Canada.

Walsh R, Shields A, Girnita A, Wall G, Brailey P, Arend L, Cardi M, Govil A, Tevar A, Safdar S, Alloway R, Woodle E (08-2010. )Comparative efficacy of proteasome inhibitor-based antihumoral therapy for early versus late post-transplant antibody mediated rejected in kidney transplant .Vancouver, Canada.

Walsh R, Shields A, Govil A, Mogilishetty G, Roy-Chaudhury P, Wall G, Cole L, Huang S, Cardi M, Safdar S, Alloway R, Woodle E (08-2010. )Proteasome inhibitor-based antihumoral therapy associated peripheral neuropathy: a prospective analysis in renal transplant candidates and recipients .Vancouver, Canada.

Schmidt N, Woodle E, Alloway R, Mogilishetty G, Tevar A, Young S, Cole L, Hanseman D, Shields A (04-2011. )Early corticosteroid withdrawal reduces risk for actual cardiovascular events in renal transplant recipients: A multivariate analysis .Cambridge, MA.

Sadaka B, Alloway R, Girnita A, Brailey P, Mogilishetty G, Woodle E (04-2011. )Multivariate analysis of risk factors that influence graft survival following proteasome inhibitor (PI) therapy for antibody-mediated rejection .Boston, MA.

Sadaka B, Woodle E, Light J, Franklin C, Morrow W, Joseph J, Rubin M, Goebel J, Baran D, Browne B, Gill J, Shapiro R, Eckman P, Mahle W, Lewis R, Gabardi S, Roberti I, Girnita A, Hanseman D, Wall G, Alloway R (05-2011. )Factors that influence donor specific antibody response to proteasome inhibitor treatment for antibody mediated renal allograft rejection: Multivariate analysis from a multicenter collaborative effort .Philadelphia, PA.

Sadaka B, Alloway R, Girnita A, Brailey P, Mogilishetty G, Hanseman D, Woodle E (05-2011. )Multivariate analysis of factors that influence donor specific antibody response to proteasome inhibitor treatment for antibody mediated rejection .Philadelphia, PA.

Schmidt N, Woodle E, Alloway R, Govil A, Cole L, Young S, Hanseman D, Rike A (05-2011. )Cardiovascular events and cardiovascular-related mortality after renal transplantation: Effect of maintenance steroid therapy .Philadelphia, PA.

Schmidt N, Alloway R, Sadaka B, Wall G, Shields A, Woodle E (05-2011. )Intermediate-term global toxicity analysis of proteasome inhibitor-based antihumoral therapy .Philadelphia, PA.

Schmidt N, Woodle E, Alloway R, Mogilishetty G, Tevar A, Young S, Cole L, Hanseman D, Shields A (05-2011. )Early corticosteroid withdrawal reduces risk for actual cardiovascular events in renal transplant recipients: A multivariate analysis .Philadelphia, PA.

Schmidt N, Shields A, Alloway R, Mogilishetty G, Cardi M, Munda R, Tevar A, Burns J, Kremer J, Cole L, Young S, Hanseman D, Safdar S, Woodle E (05-2011. )10-year experience with early corticosteroid elimination in kidney transplantation: Analysis of patient and graft survival .Philadelphia, PA.

Honors and Awards

Pharmacy School Honor Council Vice President

Outstanding Young Women of America

Transplant Pharmacist Profile

2002 Who's Who Outstanding Professionals - Honored Member

2007 Leading Women of Cincinnati - Research and Technology

2007 Fellow, American College of Clinical Pharmacy

Student Advising

Basma Sadaka, PharmD Preceptor 07-2011

Nicole M Schmidt, PharmD Preceptor Status:Completed 07-2011

R. Carlin Walsh, PharmD Preceptor Status:Completed 08-2009

Jennifer Lynne Hibbs, PharmD Preceptor Status:Completed 08-2009

Ruth Ann Lee, PharmD Preceptor Status:Completed 08-2008

Matthew J Everly, PharmD Preceptor Status:Completed 01-2008

Stacey Balducci, PharmD Preceptor Status:Completed 07-2006

Jennifer Walker, PharmD Preceptor Status:Completed 07-2005

Adele H Rike, PharmD Preceptor Status:Completed 07-2005

Tiffany Kaiser, PharmD Preceptor Status:Completed 07-2005

Kim Ueda, PharmD Preceptor Status:Completed 07-2005

Christin Rogers, PharmD Preceptor Status:Completed 08-2003

Robyn Boardman, PharmD Preceptor Status:Completed 01-2003

Meredith Aull, PharmD Preceptor Status:Completed 08-2001

Karen Hardinger, PharmD Preceptor Status:Completed 08-2000

Marsha Honaker, PharmD Preceptor Status:Completed 08-2000

Agnes Lo, PharmD Preceptor Status:Completed 08-1999

Jennifer Trofe, PharmD Preceptor Status:Completed 06-1999

Troy Somerville, PharmD Preceptor Status:Completed 07-1998

Chris Hurst Preceptor Status:Completed 03-1998

Mark Chaballa, PharmD Preceptor Status:Completed 06-1997

James Thielke, PharmD Preceptor Status:Completed 07-1996

Wendy Russell, PharmD Preceptor Status:Completed 07-1995

Kutay Demirkan, PharmD Status:Completed 07-1999

Steve Nolan, PharmD Status:Completed 07-1998

Valerie Strayhorn, PharmD Status:Completed 07-1997

Cheryl Corley, PharmD Status:Completed 07-1995

Richard Jennings, PharmD Status:Completed 07-1994

Greta Heiliker, PharmD Status:Completed 07-1993

Tiffany Kelso, PharmD Status:Completed 07-1992

Ronald Joe, PharmD Status:Completed 07-1991

Post Graduate Training and Education

1984-1988 PharmD, University of Tennessee College of Pharmacy, ,Memphis, TN

1988-1989 Residency, ASHP Approved General Clinical Residency, Veteran's Administration Medical Center, ,Memphis, TN

09-1993Immunotherapeutics Traineeship , Vanderbilt University Medical Center, ,

Keywords

renal, kidney, liver, pancreas, transplant, immunosuppressive regimens, renal, nephrology

Professional Affiliation

1997 -To Present: American Society of Transplantation

2009 -2011: Chair Elect Transplant Pharmacy Community of Practice

2011 -2013: Chair Transplant Pharmacy Community of Practice

2013 -2015: Past Chair Transplant Pharmacy Community of Practice

2011 -To Present: Awards and Nominating Committee Transplant Pharmacy Community of Practice

2011 -To Present: Public Policy Committee Transplant Pharmacy Community of Practice

1998: Immunology/Transplant PRN Chair American College of Clinical Pharmacy

2007: Fellow American College of Clinical Pharmacy

1991 -To Present: American College of Clinical Pharmacy

2004 -To Present: Ohio College of Pharmacy

1991 -2000: Mid-South College of Clinical Pharmacy

1996: President Mid-South College of Clinical Pharmacy

1995: President Elect Mid-South College of Clinical Pharmacy

American Society of Hospital Pharmacists

American Pharmaceutical Association

Rho Chi Pharmaceutical Honor Society

Beta Beta Beta Biological Honor Society

Contact Information

Academic - Medical Sciences Building
Room 6203
Cincinnati  Ohio, 45267-0585
Phone: 513-558-1568
Fax: 513-558-4944
rita.alloway@uc.edu